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Acute kidney injury (AKI) is the transient loss of renal function following an insult. Despite high 
incidence and mortality, therapy for AKI is limited to supportive care and renal replacement 
therapy. The induction of mitochondrial biogenesis (MB) accelerates recovery of renal function 
in animal models of AKI. We have identified that the beta-2 adrenergic receptor (β2AR) agonist 
formoterol induces MB in renal proximal tubule cells (RPTC); however, not all β2AR agonists 
induce MB. We hypothesized that formoterol activates a distinct signaling pathway in RPTC to 
induce MB and accelerate recovery of renal function. In cultured RPTC, we found that formoterol 
activates a Gβγ-Akt-eNOS-cGMP pathway. Clenbuterol, a β2AR agonist that does not induce 
MB, did not activate this pathway. Formoterol, but not clenbuterol, increased mRNA expression 
of PGC-1a and NDUFS1; mtDNA copy number; and FCCP-uncoupled respiration at 24 h in 
RPTC. Inhibition of Gβγ, Akt, NOS, and guanylate cyclase prevented formoterol-induced 
increases in these markers of MB. To assess the role of proximal tubule β2AR in formoterol-
induced recovery of renal function, a mouse with proximal tubule-specific deletion of the β2AR 
(γGT-Cre:ADRB2Flox/Flox) was generated. Following bilateral renal ischemia reperfusion, γGT-
Cre:ADRB2Flox/Flox and wild-type controls (ADRB2Flox/Flox) were treated once-daily with 0.3 
mg/kg formoterol beginning at 24 h. At 144 h post-injury, ADRB2Flox/Flox mice treated with 
formoterol had improved renal function and increased markers of MB relative to vehicle controls, 
while γGT-Cre:ADRB2Flox/Flox mice treated with formoterol did not. Furthermore, transmission 
electron microscopy demonstrated that in ADRB2Flox/Flox mice, but not in γGT-Cre:ADRB2Flox/Flox 
mice, formoterol increased mitochondrial number and density relative to vehicle controls. 
Together, these data demonstrate that formoterol activates a Gβγ-Akt-eNOS-cGMP to induce MB 
in RPTC and that following AKI, formoterol acts on RPTC β2AR to induce MB and accelerate 


















Acute Kidney Injury 
Acute kidney injury (AKI) is the rapid and usually reversible loss of renal function. The decline 
in renal function leads to the dysregulation of electrolytes and other metabolites, and it increases 
the likelihood of future bouts of AKI and the development of chronic kidney disease (CKD) and 
end-stage renal disease (ESRD). Current clinical standards as established by the 2012 Kidney 
Disease: Improving Global Outcomes (KDIGO) guidelines define AKI as: an increase in serum 
creatinine of >0.3 mg/dL within 48 h, an increase in serum creatinine to >1.5 times the baseline 
within the last seven days, or a urine output of <0.5 mL/kg/h for 6 hours. Under these standards, 
patients with AKI are classified into the following stages: 
Stage 1: increase in serum creatinine to 1.5-1.9 times the baseline, OR increase in serum 
creatinine by >0.3 mg/dL, OR reduction in urine output to <0.5 mL/kg for 6-12 h. 
Stage 2: increase in serum creatinine to 2.0-2.9 times the baseline, OR reduction in urine 
output to <0.5 mL/kg/h for >12 h. 
Stage 3: increase in serum creatinine to 3.0 times baseline, OR increase in serum 
creatinine to >4.0 mg/DL, OR reduction in urine output to <0.3 mL/kg/h for >24 h, OR 
anuria for >12 h, OR the initiation of renal replacement therapy, OR a decrease in 
estimated glomerular filtration rate (eGFR) to <35 mL/min/1.73 m2 in pediatric patients.1 
AKI affects over 20% of hospitalized patients and over 50% of patients in intensive care 
settings and carries a mortality rate of greater than 20%.2,3 The causes of AKI are classified as 
prerenal, intrinsic, or postrenal.4-6 Prerenal AKI is caused by drastic decreases in renal perfusion 
such as in diarrhea, acute hemorrhage, or hypovolemic states (e.g., heart failure, liver disease). 
Prerenal disease may also be caused by pharmacologic agents that interfere with renal vascular 
tone, such as nonsteroidal anti-inflammatory drugs (NSAIDS), ACE inhibitors, or radiopaque 
contrast. Intrinsic AKI is caused by direct damage to the renal vasculature, glomeruli, tubules, or 
interstitium. The most common cause of intrinsic AKI, and of AKI in general is acute tubular 
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necrosis (ATN) following ischemia, sepsis, or nephrotoxicant exposure.6 Finally, postrenal AKI 
is caused by obstruction along the urinary tract. In healthy patients, the obstruction usually 
impacts all functioning kidneys, such as in prostatic hyperplasia or cancer, metastatic cancer, or 
retroperitoneal fibrosis involving the ureters. As both prerenal and postrenal causes of AKI can 
lead to ATN if untreated, many patients have multiple causes for developing AKI, thereby 
complicating treatment. Additionally, the current biomarkers of serum creatinine and urine output 
do not change until significant losses in renal function have already occurred,7 thereby 
complicating the identification of relevant renal insults. 
Most patients with AKI exhibit a full recovery of renal function within 21 days as measured 
by serum creatinine and urine output. A recent study also identified three subtypes of recovery 
from AKI:  
1. An early (within seven days of diagnosis) and sustained recovery; 
2. An early recovery followed by relapse and subsequent recovery; and  
3. A late (greater than seven days after diagnosis) recovery.8  
Sustained recovery was the most common and had the best prognosis, while a late recovery was 
the least common but still had improved survival at 12 months compared with patients who did 
not recover from AKI or underwent a relapse from which they did not recover. Furthermore, 
patients with prior incidents of AKI had a greater likelihood of developing CKD or ESRD,9-13 
indicating that there was some persistent renal dysfunction following AKI. Interestingly, the 
major causes of in-hospital mortality are often infection or the underlying condition that causes 
AKI.14 
Due to their renal dysfunction, patients with AKI may exhibit fluid retention and ion 
imbalances, particularly hyperkalemia or hyponatremia; however, many patients develop no 
symptoms and their diagnosis is only identified by routine laboratory tests for serum creatinine.15 
Despite the initially silent presentation, AKI leads to dysfunction in multiple other organ systems. 
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The most commonly described distant manifestation of AKI is cardiorenal syndrome, with the 
term “cardiac failure” being used to describe cause of death in AKI patients.16 There is an 
established relationship between AKI and the development of heart failure and arrhythmias as 
well as other forms of cardiovascular disease such as hypertension.17,18 These outcomes may be 
due to fluid overload, endothelial cell activation, and inflammatory cytokines leading to cardiac 
cell death.19 Animal models of AKI have shown cardiac dysfunction characterized by left 
ventricular dilation, increased relaxation time, and decreased fractional shortening.20 
In addition to the cardiac effects of AKI, dysfunction of several other organ systems has 
been correlated with AKI. Patients with pulmonary dysfunction such as acute respiratory distress 
syndrome (ARDS) had a greater incidence of AKI and greater mortality following AKI.21-23 Many 
patients who develop AKI also developed respiratory failure and associated increases in the 
inflammatory cytokines IL-6 and IL-8.23-27 Animal models of AKI have demonstrated increased 
pulmonary vascular permeability and fluid accumulation following AKI due to decreased 
expression of epithelial sodium channels (eNACs) and aquaporins.28-30 Different causes of AKI 
(e.g., sepsis, ischemia reperfusion, nephrectomy) in animal models also had distinct profiles of 
inflammatory cytokines in the lungs.29,31 In the central nervous system, uremic encephalopathy 
and other forms of altered mental status have been associated with AKI,32,33 but the pathogenesis 
is not well understood in humans. In the brains of animals subjected to AKI, there were 
alterations in calcium and water handling and dopamine turnover along with disruption of the 
blood brain barrier and increases in inflammation.34-37 As a result, these animals exhibited 
diminished locomotor function. Despite these changes, there were no observed increases in 
apoptosis in the brain. 
Because AKI has such profound effects on patient health, the underlying processes that 
lead to injury must be understood to improve the prevention, detection, and therapy of AKI. As 
acute tubular necrosis is associated with such a large proportion of AKI cases, much of the work 
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understanding the pathophysiology of AKI has focused on the proximal tubule. Proximal tubule 
injury has been shown to be sufficient for the development of AKI and, perhaps more 
importantly, the transition to CKD. 
Since AKI leads to severe and systemic complications, the early identification of AKI is 
important.38 Clinically, the standard biomarkers are serum creatinine (SCr) as a measure of eGFR 
and urine output. However, as creatinine is affected by muscle mass,39 an increase in SCr may be 
masked by muscle wasting; this may be found in elderly patients or patients undergoing cancer 
chemotherapy. SCr is also relatively insensitive to decreases in GFR.40 While serial 
measurements of creatinine can help improve diagnosis of AKI, serial measurements are not 
always available. Both SC and urine output are also measures of renal function rather than of 
renal injury and are therefore unable to distinguish among different etiologies of AKI.41 As a 
result, neither of these metrics alone is necessarily able to predict mortality or disease 
severity.42,43 To facilitate the early diagnosis of AKI and better guide treatment decisions, more 
sensitive and more specific biomarkers are needed (Figure 1-1). 
Neutrophil gelatinase-associated lipocalin (NGAL) is expressed by neutrophils and binds 
to iron-siderophore complexes to prevent bacterial growth.44,45 Following ischemia- or 
nephrotoxicant-induced AKI, NGAL expression is rapidly upregulated,46,47 with elevated levels 
appearing at 3 h and persisting for up to 5 days in cases of severe injury. Within the kidney, 
NGAL is mainly produced by the thick ascending loop of Henle and the intercalated cells of the 
collecting duct.48,49 NGAL is freely filtered by the glomerulus and is reabsorbed in the proximal 
tubules.50 Once reabsorbed, NGAL upregulates the renoprotective enzyme heme-oxygenase 1.51 
Clinically, NGAL elevations preceded SCr increases, and NGAL is only elevated in the setting of 
damage to the kidney itself (i.e., intrinsic AKI, particularly that involving proximal tubule injury) 
rather than more rapidly reversible prerenal AKI.52-54 The elevation of NGAL matched the 
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Figure 1-1. Sites of synthesis of novel biomarkers for the diagnosis of AKI. The many cell types 
of the nephron increase the expression of different markers following AKI. These biomarkers can 
be used to diagnose AKI, determine the causal insult, and monitor responses to therapy in human 
patients and animal models. Adapted from Schrezenmeier E.V., et. al. Biomarkers in Acute 
Kidney Injury. Acta Physiol 2016. 
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duration of AKI and predicts disease severity in terms of death or need for renal replacement 
therapy.  However, because NGAL is expressed by neutrophils, it is also associated with sepsis,55 
chronic kidney disease,56 and urinary tract infections,40,49 so other biomarkers are required to 
confirm the presence of AKI. 
Liver-type fatty acid binding protein (L-FABP) binds to fatty acids and transports them to 
mitochondria and peroxisomes for metabolism.57 It also plays a role in antioxidant defense 
against hydrogen peroxide. In the kidney, L-FABP is primarily expressed in proximal tubules, 
where it is excreted bound to toxic peroxisomal byproducts.58,59 Expressing L-FABP in mice 
reduced injury and preserved renal function following renal ischemia;59,60 however, since mice do 
not normally express L-FABP, human-L-FABP transgenic mice are required to study the effects 
of L-FABP preclinically.60,61 Clinically, L-FABP predicted the development of AKI in an 
intensive care unit (ICU) setting following surgery,62 sepsis,63 or nephrotoxicant exposure.64 
However, there are limited data regarding the predictive value of L-FABP for mortality or end-
stage renal disease.38 
Inteleukin-18 (IL-18) is a cytokine secreted by monocytes/macrophages during 
inflammation to induce the production of IFN-γ.65 Following toll-like receptor (TLR) activation, 
other inflammatory signals, or injury, tubular cells produce IL-18.66 Deficient IL-18 production or 
inhibition of its signaling was protective against AKI in rodent models.67-71 As a biomarker, IL-18 
had predictive value for AKI following kidney transplant and in pediatric patients but not in the 
ICU or ER settings.53,72-75 More importantly, IL-18 may have value for guiding anti-IL-18 
treatment decisions for patients with AKI.38 
Cell cycle arrest in the G1 phase has been demonstrated following ischemic or septic AKI 
and is protective in animal models of nephrotoxic AKI.76-79 IGF-binding protein 7 (IGFBP7) and 
tissue inhibitor of metalloproteinase-2 (TIMP-2) induce cell cycle arrest in multiple cell types, 
including breast and colon cancer and microvascular cells.80-82 Additionally, urinary 
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concentrations of both TIMP-2 and IGFBP7 were elevated following AKI in rodents and 
humans.83,84 However, there are no experimental data for their involvement in the renal cell cycle 
arrest, and the source of these proteins following AKI is unclear.38 Clinically, the product of the 
concentrations of IGFBP7 and TIMP-2 was a good predictor of severe (stage 2 or 3) AKI,85,86 
mortality,87 and the need for renal-replacement therapy in ICU settings.87 
Calprotectin is an intracellular heterodimeric protein that, when secreted, acts as a 
damage-associated molecular pattern (DAMP) that can activate TLR4.88 Its monomers are 
produced by collecting duct epithelial cells following postrenal AKI and by neutrophils following 
renal ischemia.89,90 Neutrophil-secreted calprotectin promotes the recruitment of inflammatory 
monocytes and their differentiation into M1 macrophages.90 However, following the initial injury, 
calprotectin plays a role in the prevention of renal fibrosis and promoting proper repair of the 
kidney. In patients undergoing renal surgery, calprotectin was increased at 2 h following injury 
and remained elevated for 5 days.91 Calprotectin also accurately distinguished prerenal AKI from 
intrinsic AKI.92 The clinical utility of calprotectin is limited by its upregulation by neutrophils in 
inflammatory states, such as urinary tract infections,38 and by the kidney in urothelial 
carcinoma.93 
 Kidney injury marker-1 (KIM-1) is a transmembrane protein with an immunoglobulin-
like domain that is expressed in a variety of cell types.94 Following ischemia-reperfusion injury, 
KIM-1 is rapidly upregulated by proximal tubule cells and is shed into the urine in a matrix 
metalloproteinase-dependent manner.94-99 The increased expression and shedding of KIM-1 
makes it a sensitive and specific urinary biomarker for proximal tubule cell injury. KIM-1 binds 
to phosphatidylserine on apoptotic bodies and other cellular debris to mediate their 
phagocytosis.100 In so doing, KIM-1 preserves renal function and attenuates the inflammatory 
response as demonstrated by mice expressing mutant KIM-1.101 However, the severity of kidney 
injury impacts the efficiency of KIM-1 phagocytosis, as excessive shed KIM-1 can inhibit its own 
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debris clearance.102 KIM-1 also binds to and antagonizes Gα12 as a guanine dissociation 
inhibitor.103 In AKI, Gα12 disrupts tight junctions in a Src-dependent manner;104 thus, KIM-1-
mediated inhibition of Gα12 preserved tubular structure in AKI.103,105 However, in chronic kidney 
disease, KIM-1 expression correlated with a greater degree of inflammation and fibrosis.106-108 
Clinically, KIM-1, particularly in conjunction with IL-18, was an excellent biomarker of AKI 
following cardiac surgery and had predictive value for both intrinsic AKI and in-hospital 
mortality.109 Because it is upregulated in a variety of proteinuric and inflammatory diseases,107 its 
specificity for AKI can be limited in the clinic, but its sensitivity and specificity for tubular cell 





Cell Types Involved in AKI 
Most forms of intrinsic AKI are characterized by injury of the proximal tubule cell. The 
proximal tubule performs over 70% of solute reabsorption and secretion in the glomerular 
filtrate,112 so the loss of its integrity has a highly detrimental effect on ion homeostasis and proper 
excretion of metabolic byproducts. Additionally, several key functional features of proximal 
tubule cells,113 such as a brush border, drug metabolizing enzymes, and high mitochondrial 
content to accommodate their high energy demands, increase their susceptibility to nephrotoxic 
agents and other sources of injury. 
Beyond the nephron, the kidney contains numerous other cell types, including 
endothelial, interstitial, and inflammatory cells (Figure 1-2). While the proximal tubule cell plays 
an important and often causative role in the initial injury in AKI, these other cell types play an 
important role in the propagation of injury and its resolution. 
ENDOTHEIAL AND VASCULAR RESPONSES: Ischemic AKI causes increased 
production of endothelin-1, angiotensin II, thromboxane A2, prostaglandin A2, leukotrienes C4 
and D4, and adenosine, as well as an increase in sympathetic nerve activation.114-117 These 
responses lead to substantial vasoconstriction. There is also a decrease in production of 
vasodilatory molecules like acetylcholine, bradykinin, and nitric oxide.118,119 Endothelial 
activation produces chemokines and adhesion molecules that recruit inflammatory cells such as 
neutrophils and monocytes.120-122 These inflammatory cells release vasoactive cytokines and 
cause occlusion of small vessels by leukocyte-endothelial interactions and activation of the 
coagulation cascade.120 Additionally, tubulo-glomerular feedback due to diminished sodium 
reabsorption in injured nephrons leads to further arteriolar vasoconstriction, further reducing 
glomerular filtration.123 As the endothelium becomes damaged, its barrier function declines,124 
leading to interstitial edema. Following injury, an imbalance in angiogenic factors decreases the 
number of capillaries,125,126 particularly on the inner stripe of the outer medulla. As a result, the   
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Figure 1-2. Involvement of numerous cell types in the pathogenesis of AKI. Following injury, 
endothelial and immune cells are activated and modulate injury progression and recovery from 
AKI. Different cell types are recruited depending on injury severity, and these cell types can 
negatively (neutrophils, M1 macrophages, fibroblasts) or positively (M2 macrophages, TH2 cells, 
TReg cells) regulate recovery from AKI. Adapted from Kumar S. Cellular and Molecular Pathways 
of Renal Repair After Acute Kidney Injury. Kidney Int. 2017.  
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outer medulla is subjected to further hypoxia ,which sensitizes it to further injury and promotes 
maladaptive repair processes like fibrosis.127 
INFLAMMATION: As renal cells are damaged in AKI, they release DAMPs that are 
recognized by the innate immune system to mount a systemic inflammatory response.128 
Following AKI, receptors for DAMPs, such as TLR2 and TLR4, were upregulated in renal 
cells.129,130 Upon TLR activation, NFκB was activated to induce the expression of pro-
inflammatory cytokines, such as TNF-α, IL-6, MCP-1, and IL-8.131,132 These cytokines recruited 
other inflammatory cells, such as macrophages, neutrophils, and lymphocytes. HIF-1α activation 
within the kidney also enhanced macrophage infiltration following injury.133 Additionally, 
activation of the endothelium (as described above) led to increased expression of adhesion 
molecules that recruit and activate immune cells. Once activated, immune cells secreted TNF-α 
and IFN-γ, which themselves can induce cell-death,134 thereby leading to a necroinflammatory 
cascade. 
Neutrophils, macrophages, dendritic cells, and lymphocytes are recruited to the kidney 
during the injury phase of AKI. Increased IL-8 secretion following injury increased neutrophil 
infiltration into the injured kidney.135-137 Neutrophils also secrete IL-17, which promotes further 
neutrophil recruitment.138 Once activated, neutrophils play a variety of roles,139 including 
phagocytosis, ROS generation, cytotoxic peptide release, and NETosis, a process by which 
neutrophils release histones, DNA, and cytotoxic granules to trap and kill pathogens.137 Although 
neutrophils have been observed in animal models of AKI and patient biopsy samples, targeting 
neutrophils to treat AKI has yielded mixed results.140-142 
Macrophages, particularly of the M1 phenotype, contribute to early injury by recruiting 
neutrophils, secreting cytokines, and inducing apoptosis.139 Systemic depletion of macrophages in 
mice attenuated renal ischemia reperfusion injury.143,144 At later time points, M1 macrophages 
played a pro-fibrotic role, potentiating the AKI-CKD transition.145,146 A switch to the anti-
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inflammatory M2 phenotype protected against renal injury and promotes recovery following an 
insult.147,148 This switch can be mediated by the increased proliferation of resident renal 
macrophages via CSF-1 or IRAK stimulation.149-151  
While traditionally associated with delayed immune responses, various classes of 
lymphocytes play important roles in the development of AKI. Natural killer (NK) cells were 
activated by tubular osteopontin, leading to apoptosis of tubular epithelial cells.152 NK T cells, 
which display both NK and T-cell markers,153 can play a pathologic or a therapeutic role in AKI. 
NK T cells secrete pro-inflammatory cytokines such as IL-4, IL-10, and IFN-γ to recruit IFN-γ 
producing neutrophils.154,155 General inhibition of NK T cells reduced the infiltration of IFN-γ 
producing neutrophils and attenuated renal injury.156 However, specific inhibition or depletion of 
type II NK T cells increased injury, while activation of type II NK T cells by sulphatide 
attenuated injury.157 
Regulatory T (TREG) cells have been reported to have anti-inflammatory properties in 
numerous disease models. In the early phase of injury, TREG cells secreted IL-10 to suppress the 
innate immune system and thereby attenuated renal injury.158 TREG cells trafficked to the kidney in 
the late injury phase,159 whereupon they reduced inflammation and promoted tubular repair and 
regeneration.158 Experimentally, inhibition or depletion of TREG cells was detrimental to renal 
function,158 while their expansion or activation promoted recovery.160-162 However, the small 
number of TREG cells in the kidney raises questions regarding the mechanism by which TREG cells 
so potently modulate inflammatory responses despite their small population.139 
CD4+ and CD8+ T cells are well-studied in multiple organ systems, and several therapies 
exist to selectively suppress these populations of inflammatory cells. T cell depletion by 
tacrolimus or inhibition of T cells with anti-CTLA-4 immunoglobulin reduced early injury in 
models of transplant-induced AKI.163-165 Other work has shown that depletion of CD4+ and CD8+ 
cells protected against injury following ischemia reperfusion-induced AKI,166,167 while adoptive 
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transfer of T cells restored injury. More specifically, CD4-knockout mice exhibited less injury 
following ischemia reperfusion,167 and this protection was abrogated by adoptive transfer of CD4+ 
T cells. Blockade of IL-16, a cytokine that recruits CD4+ T cell recruitment, reduced not only T-
cell infiltration but also renal injury.168 Much like macrophages, CD4+ T cells can exhibit multiple 
phenotypes. The inflammatory TH1 phenotype is produced by STAT-4 activation and produces 
IFN-γ, while the anti-inflammatory TH2 phenotype is produced by STAT6 activation to produce 
IL-4. STAT4-deficient mice (i.e., mice unable to generate the TH1 phenotype) exhibited partial 
protection against AKI, but injury in STAT6-deficient mice (i.e., mice unable to generate the TH2 
phenotype) was potentiated.169 While the role of CD8+ cells in the pathogenesis of AKI has not 
been fully determined, evidence from germ-free mice showed that naïve CD8+ T cells infiltrate 
the kidney following injury and produce IFN-γ to increase injury.170 Even after the initial phase of 
injury, activated and memory T cells remained in the kidney,171 suggesting that these cells may 
play a role in the pathogenic remodeling that leads to chronic kidney disease. 
B lymphocytes (B cells) are recruited to the kidney following injury,172 and mice 
deficient in B cells were protected from renal injury and exhibited more tubular repair during the 
recovery phase.173 Adoptive transfer of B cells blocked the effects on recovery,172 indicating that 
B cells may be a viable therapeutic target for AKI, particularly since most AKI patients are 
identified after the initial insult has occurred.  
RENAL PROXIMAL TUBULE CELLS: Perhaps the central cell types in the 
pathogenesis of AKI is the renal proximal tubule cell (RPTC).174 These cells are part of the renal 
epithelium and are responsible for the bulk of solute secretion and reabsorption into the urinary 
filtrate.112 As a result, RPTC require a great deal of ATP and are therefore highly oxidative, 
containing numerous mitochondria.175,176 However, this oxidative phenotype and high transport 
burden makes RPTC susceptible to injury following oxidative stress (such as by renal ischemia) 
or nephrotoxicant exposure. RPTC play important injury-sensing roles in the kidney and signal to 
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immune cells, endothelial cells, and fibroblasts during AKI to mediate injury and repair 
processes.113 Importantly, transgenic mouse models that selectively injure or deplete RPTC have 
demonstrated that AKI severity correlates with the degree of RPTC loss.177-179 Furthermore, 
RPTC injury and loss was sufficient to promote injury pathways in distal tubules and fibroblasts, 
underscoring the central importance of RPTC even in a multicellular pathology like AKI. These 
data were further corroborated by studies blocking p53-mediated apoptosis in RPTC,180,181 
wherein prevention of RPTC apoptosis protected against ischemic AKI. 
Following AKI, RPTC underwent a loss of polarity with redistribution of transporters 
(e.g., Na+/K+ ATPase) and disruption of the actin cytoskeleton.182 This was accompanied by a 
downregulation of mitochondrial metabolism and cell-cycle arrest to maintain cell membrane 
potential and energy balance. Additionally, integrins translocated from the basolateral to the 
apical surface (i.e., from basement membrane to tubular lumen).183 As injury progressed, dead 
and intact RPTC sloughed into the tubular lumen and bound to these integrins, causing tubular 
obstruction and further injury. Damage- and pathogen-associated molecular patents (DAMPs and 
PAMPs, respectively) within the tubular debris were recognized by toll-like receptors, 
particularly TLR 2, TLR 4, and TLR 9.184,185 These receptors were responsible for upregulation of 
inflammatory cytokines that enhance injury by reducing blood flow (leading to local hypoxia) 
and activating the innate immune system.127 Additionally, RPTC lost expression of Crry,186 a 
complement inhibitor, which led to increased inflammation and cell death. RPTC also regulated 
later immune responses by T-cells via MHC II expression.187 
Following injury, RPTC upregulate the expression of injury markers, such as NGAL and 
KIM-1, described above. NGAL, along with other siderophores, scavenges iron to mitigate the 
propagation of oxidative stress.188 KIM-1 acts a receptor for phosphatidylserine-mediated 
phagocytosis,100 blocking pro-inflammatory signals and promoting clearance of luminal debris. 
However, chronic KIM-1 upregulation led to fibrosis by inducing MCP-1 and TGF-β expression 
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to recruit macrophages and fibroblasts.106 This fibrotic signaling was exacerbated by Wnt,189 
Notch,190,191 and TGF-β signaling pathways in the proximal tubules.192,193 
Although proximal tubule cells are susceptible to injury, they also display substantial 
regenerative capacity. In the setting of mild ischemia, epithelial cells repolarized and returned to 
their healthy oxidative state.194 Following more severe injury, loss of RPTC into the lumen 
necessitated regeneration.195 RPTC dedifferentiate following injury,196 while regenerated tubules 
have differentiated and functional RPTC. This finding raised questions of whether a stem or 
progenitor cell population might be responsible for tubular recovery. Examinations of lineage and 
clonal behavior have shown that terminally differentiated RPTC (rather than stem or extrarenal 
progenitor cells) were able to migrate, proliferate, and redifferentiate to generate functional 
tubules.197,198 However, this repair was incomplete, as injured kidneys had shortened proximal 
tubule cells.199 This finding may explain the increased susceptibility of patients with AKI to 
future bouts of AKI or development of CKD and ESRD. 
Mitochondria and AKI: 
The proximal tubules have an extensive role in the reabsorption and secretion of solutes 
from and into the glomerular filtrate. As a consequence, they consume a great deal of ATP and 
have a dense mitochondrial network. Disruption of or damage to this mitochondrial network led 
to morphological and functional deficits of the proximal tubules.200 In addition to their role in 
generating ATP, mitochondria also play key roles in the regulation of ROS, steroid and heme 
biosynthesis, calcium and iron handling, and apoptosis.176 The mitochondrial network is highly 
dynamic with mitochondria undergoing fission, fusion, and turnover (mitophagy) in response to 
cellular conditions. Therefore, mitochondrial dysfunction can lead to severe cellular 
consequences beyond the disruption of ATP-dependent processes.  
Patients with mitochondrial diseases (that is, diseases due to mutations in the mtDNA or 
nuclear-encoded mitochondrial genes) often present with renal manifestations such as proteinuria, 
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metabolic acidosis, or progressive renal failure.201,202 Histologically, their kidneys demonstrated 
tubular atrophy, interstitial nephritis, or glomerular involvement (such as focal segmental 
glomerular sclerosis). 
Many causes of AKI, particularly intrinsic AKI, have associated mitochondrial 
dysfunction. Cisplatin inhibited the electron transport chain, diminished respiratory capacity and 
mitochondrial membrane potential, and activated mitochondrial cell death pathways.203 Ischemia 
reperfusion injury led to an increase in ROS production,204 which disrupted respiration and 
damaged the mitochondria, leading to subsequent cell death. Numerous models of AKI, such as 
sepsis,205,206 glycerol-induced rhabdomyolysis,207 folic acid,208 and ischemia-reperfusion injury,207 
exhibited a persistent suppression of mitochondrial proteins, particularly subunits of the electron 
transport chain. Importantly, mitochondrial dysfunction preceded clinical manifestations of 
AKI,209 suggesting that mitochondria play a causative role in the development of AKI. Samples 
from patients with various renal insults including trauma,210 sepsis,211 and ischemia have 
demonstrated swollen mitochondria and mitochondrial vacuolization, even with normal renal 
histology and function.209 
 Following AKI, proximal tubules exhibited increased mitophagy, or the selective 
degradation of mitochondria. Mitophagy occurs through two main pathways.212,213 In one, the 
PINK1/Parkin pathway, PINK1 accumulates on the outer membrane of damaged mitochondria, 
where it binds the E3 ubiquitin ligase Parkin. Parkin then ubiquitinates mitochondrial proteins, 
which in turn bind to p62 and optineurin on the autophagosome. In the other pathway, the 
BNIP3/NIX/FUNDC1 pathway, BNIP3, NIX, and FUNDC1 on the outer mitochondrial 
membrane act as mitophagy receptors that bind LC3 on the autophagosome. By increasing 
mitophagic flux, cells can clear damaged and dysfunctional mitochondria to prevent excessive 
oxidative stress while maintaining ATP production. Both BNIP3 and PINK1 were increased 
following AKI,214,215 and the induction of mitophagy was protective against AKI.216,217 Mice fed 
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low-calorie diets had increased renal mitophagy with less oxidative stress,218 leading to protection 
against AKI. Furthermore, activation of AMPK increased autophagy to protect against AKI by 
inhibiting mTOR, an inhibitor of autophagy.219,220 However, direct inhibition of mTOR by 
rapamycin failed to prevent loss of renal function and inhibits tubular proliferation,221-223 despite 
inducing autophagy. These effects were likely due to the role of mTOR in numerous cellular 
processes, including survival and proliferation.  
Under normal conditions, mitochondria are dynamic organelles that undergo frequent 
fission and fusion events. Mitochondrial fission is mediated by dynamin-related protein 1 (Drp1) 
and its receptor, Fis1, while mitochondrial fusion is regulated by mitofusins 1 and 2 (Mfn1 and 
Mfn2, respectively) on the outer mitochondrial membrane and Opa1 on the inner mitochondrial 
membrane.224 Following various organ injuries, including AKI, mitochondria became fragmented 
and swollen.203 This was associated with an increase in Drp1 translocation to the 
mitochondria,203,207 suggesting that modulating mitochondrial dynamics might be a therapeutic 
target for AKI. Indeed, inhibition of Drp1 by mDivi-1 prevented mitochondrial fission and 
apoptosis while also rescuing renal function following AKI.203,225 Interestingly, mDivi-1 also had 
beneficial effects in mouse models of cardiorenal syndrome,226 the major cardiovascular sequela 
following AKI. Based on the beneficial effects of inhibiting fission, the effects of increasing 
mitofusin expression on AKI have been studied. In vitro, deletion of Mfn2 enhanced RPTC 
susceptibility to apoptosis.227 However, in vivo, proximal tubular deletion of Mfn2 increased 
proliferation through an ERK-dependent pathway and accelerates recovery of renal function.228 In 
animal models of CKD, renal dysfunction and increased mitochondrial fusion were reversed by 
the antioxidant curcumin.229 Together, these data indicate that while inhibition of mitochondrial 
fission is a promising therapeutic target, further study of mitochondrial fission and fusion is 
necessary to better implement therapies for AKI. 
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While mitophagy and mitochondrial fission decrease the mitochondrial pool, suppression 
of mitochondrial biogenesis (MB) also occurs after AKI. MB is the process by which new 
mitochondria are made and requires tight coordination between the nuclear and mitochondrial 
genomes. Following AKI, the expression of electron transport chain proteins was 
suppressed,207,230,231 and ATP and mitochondrial function were decreased. One of the main 
regulators of MB is the transcriptional co-activator peroxisome proliferator-activated receptor 
gamma coactivator 1α (PGC-1α).232 Following AKI, PGC-1α expression was decreased during 
the injury phase,205,206 followed by an increase during the recovery phase. However, even in the 
recovery phase, the inactive acetylated form of PGC-1α was elevated.233 Specific deletion of 
PGC-1α in RPTC worsened injury from AKI.205 Overexpression of PGC-1α prevented TNFα-
induced decreases in oxygen consumption and mRNA expression of mitochondrial genes.205 
However, in the setting of oxidant injury, overexpression of PGC-1α worsened injury but 
accelerated recovery of RPTC.234 The latter data are of particular importance, as diagnosis of AKI 
often occurs after initial injury has occurred. Therefore, MB represents an attractive therapeutic 
target for AKI. Below, signaling pathways leading to MB and drugs that are known to induce MB 
will be discussed. 
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Inducing Mitochondrial Biogenesis to Treat Degenerative Diseases 
Mitochondria, the metabolic powerhouses of the cell, have diverse functions including 
ATP production, biomolecule synthesis, ionic homeostasis and antioxidant defense. As cells age 
and accumulate damage, mitochondria less readily meet ATP demands, thereby diminishing the 
cells’ functions and regenerative capacity. After toxicant exposure or cell stress, mitochondria can 
be damaged, and increased free radical production may be followed by persistent mitochondrial 
dysfunction. Diminished ATP and increased free radicals propagate injury and subsequent tissue 
and organ dysfunction (Figure 1-3). Indeed, many acute and chronic degenerative diseases across 
multiple organ systems are associated with a degree of mitochondrial dysfunction, often with 
suppression of electron transport chain proteins and activities.235-238 
Because many diseases are associated with mitochondrial dysfunction, research is 
underway to develop therapeutics that target mitochondria to prevent disease progression. For 
example, numerous compounds have been studied that prevent cell death by interfering with the 
formation of the mitochondrial permeability transition pore (MPTP), reducing oxidative stress 
using mitochondrial-targeted antioxidants, or modulating mitochondrial dynamics by inhibiting 
mitochondrial fission or promoting mitochondrial networking.239 However, whereas many of 
these strategies are effective for preventing injury in animal models, they target events that occur 
early in cellular dysfunction and therefore may be less efficacious for facilitating recovery after 
an insult. To address this problem, some groups have investigated compounds that induce MB, or 
the generation of new, functional mitochondria within cells to promote repair and regeneration.235 
This section will describe the role of the peroxisomal proliferation activated receptor 
coactivator-1α (PGC-1α) in MB and the role of mitochondrial dysfunction in acute and chronic 
degenerative diseases. It will also describe existing compounds that induce MB, signaling 
pathways responsible for their effects, and finally, potential utility of these compounds for   
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Figure 1-3. Multiple insults converge upon the mitochondria, leading to mitochondrial 
dysfunction and subsequent organ injury and disease. Following an insult, increased ROS 
generation leads to mitochondrial damage. Subsequent energy deficits and disrupted signaling 
lead to tissue and organ dysfunction. 
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treating human acute and chronic degenerative diseases for which there are presently limited 
therapeutic options. 
Regulation of MB  
MB requires the activation of a complex transcriptional and translational program 
integrating both nuclear and mitochondrial genomes.240,241 Nuclear encoded mitochondrial genes, 
such as the mitochondrial transcription factors and the mitochondrial DNA (mtDNA) replication 
complex, facilitate transcription, replication, and proofreading of the mitochondrial genome.240 
Integrity of mtDNA replication is particularly important in aging and chronic degenerative 
diseases, where deleterious mtDNA mutations and deletions can lead to dysfunctional 
mitochondria.242,243 For example, the nuclear transcription factors  estrogen receptor (ER) and 
estrogen related receptor-α (ERRα), nuclear respiratory factors 1 and 2 (NRF-1 and NRF-2), 
peroxisome proliferator-activated receptor (PPAR) family of transcription factors, thyroid 
hormone receptor (TR), cAMP-responsive element binding protein (CREB), and yin yang-1 (YY-
1)244 increase expression of genes of the electron transport chain, mitochondrial transporters, 
antioxidant proteins, and other mitochondrial transcription factors. However, these transcription 
factors are pleotropic with effects on genes unrelated to MB. Selective induction of MB is 
typically regulated through transcriptional co-activation proteins such as the PGC-1 family 
(Figure 1-4). PGC-1 proteins activate transcription and translation of mitochondrial genes and 
increase energy production in healthy cells, whereas in injured cells PGC-1 activation often 
normalizes overall mitochondrial function as measured by ATP production, mitochondrial 
membrane potential, and reactive oxygen species (ROS) generation.245-247 
The PGC-1 family, composed of PGC-1α, PGC-1β, and PGC-1 related coactivator 
(PRC), facilitate the formation of complexes capable of activating the transcription of nuclear 
genes related to MB.248 PRC is thought to play a role in redox-sensitive inflammatory responses 
and MB during cellular proliferation, whereas PGC-1β appears to contribute more to maintenance   
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Figure 1-4. PGC-1α integrates extracellular and cytosolic signaling inputs to selectively 
upregulate mitochondrial biogenesis. Extracellular signals from GPCRs such as beta adrenergic 
receptors (βAR), serotonin receptors (e.g., 5HT1R), and cannabinoid receptors (e.g. CB1R) 
modulate second messengers and kinase activity. These signals converge on transcription factors 
and PGC-1α to induce MB, with increased expression of tricarboxylic acid (TCA) and oxidative 
phosphorylation (OXPHOS) proteins. Various pharmacologic agents modulate these inputs and 
can therefore induce MB. Adapted from Cameron R.B. et. al. Development of Therapeutics That 
Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic Degenerative Diseases. 
J. Med. Chem. 2016.  
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of mitochondrial mass. In contrast, PGC-1α has been shown to drive MB in response to various 
environmental cues. Because PGC-1α tends to be the most inducible and responsive member of 
the PGC-1 family, its activation has emerged as a key therapeutic strategy for MB induction. 
However, it is important to note that PGC-1α-independent mechanisms of MB have been 
reported.249-252 Such mechanisms include compensatory activation of PGC-1β or PRC and direct 
activation of transcription factors that induce mitochondrial genes.  
Through activation of PGC-1α and its associated transcription factors, multiple signaling 
pathways have been shown to regulate MB. PGC-1α can be directly activated by silent mating 
type information regulation 2 homolog 1 (SIRT1)-mediated deacetylation,253 methylation by 
protein arginine methyltransferase 1 (PRMT1),254 or phosphorylation by kinases such as p38,255 
protein kinase A (PKA),256 and AMP-dependent kinase (AMPK).257 Additionally, PGC-1α and 
other transcription factors associated with MB can be activated by NO/cGMP and calcium-
dependent signaling.258 In summary, these diverse signaling inputs allow exquisite control of 
mitochondrial homeostasis to meet cellular energy demands and to maintain proper cellular 
function.  
The Importance of MB in Disease 
Because mitochondria regulate many processes within cells, mitochondrial dysfunction or 
disruptions in mitochondrial homeostasis lead to severe deficits in cellular functions.235,236 Injury 
to mitochondria following ischemia reperfusion injury, toxicant exposure, or severe inflammatory 
response leads to deficient ATP and disruption of ion homeostasis. Additionally, mitochondrial 
stress increases superoxide anion production and which causes damage to proteins and lipid 
membranes. These mitochondrial derangements disrupt cellular repair, proliferation, and 
differentiation status and increase cell death. 
Mitochondrial dysfunction has been implicated in numerous acute and degenerative 
disease processes, such as myocardial infarction,259 stroke,260 and AKI.207 These disease states 
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may be attributed in part to the role of mitochondria and oxidative metabolism in cellular 
differentiation as observed in neurons,261 myocytes,262 and immune cells.263 Chronic conditions 
causally linked to such acute insults (such as chronic kidney disease and heart failure) are also 
characterized by persistent mitochondrial dysfunction,264,265 suggesting that the lack of 
mitochondrial recovery after an acute injury can also lead to chronic degenerative disease. For 
example, deficits in PGC-1 family proteins have been associated with the development heart 
failure in both animal models and human patients.266,267 Interestingly, mice that overexpress PGC-
1 proteins also exhibit abnormal cardiac function,268 indicating that a tight control over 
mitochondrial content is necessary for normal organ function. Similarly, animal models of 
chronic kidney disease demonstrate diminished renal mitochondrial function,269 and animal 
models of mitochondrial dysfunction demonstrate chronic kidney disease.270 Finally, human 
patients with chronic kidney disease have decreased mtDNA in skeletal muscle and peripheral 
mononuclear blood cells,269 suggesting that mitochondrial defects in a single organ can lead to 
global mitochondrial dysfunction. 
Other chronic diseases also have been associated with disruption of mitochondrial 
homeostasis. Type II diabetes mellitus and metabolic syndrome are characterized by 
mitochondrial dysfunction associated with insulin resistance.271 In metabolic syndrome, 
pancreatic beta cells exhibit increases in UCP2, decreased ATP synthesis, and increased levels of 
ROS.272,273 Additionally, reductions in complex IV of the electron transport chain have been 
associated with the development of diabetes in obese mice and patients.274 Furthermore, 
epigenetic silencing of electron transport chain genes and mtDNA,275-277 along with genes 
associated with MB such as PGC-1α and TFAM,278,279 lead to decreased mitochondrial content 
and a greater proportion of dysfunctional mitochondria, thereby causing sustained deficiencies in 
cellular respiration. 
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Multiple neurodegenerative diseases also have been associated with decreased 
mitochondrial mass, altered mitochondrial dynamics, and dysregulation of MB. Parkinson disease 
has been linked to a panoply of mutations that lead to mitochondrial dysfunction. Defects in 
PINK1 and Parkin disrupt clearance of damaged mitochondria, permitting accumulation of 
oxidative damage in dopaminergic neurons and suppression of PGC-1α and decreased cellular 
respiration.280-283 Mutations in DJ-1 increase ROS while decreasing anti-oxidant defenses,284 
leading to decreases in mitochondrial membrane potential, poor mitochondrial quality control, 
and altered mitochondrial morphology. Similarly, mutations in mTDNA,285-288 TFAM,289 
mortalin,290 and α-synuclein291 lead to increased susceptibility to ROS and subsequent 
mitochondrial dysfunction. Additionally, huntingtin mutants associated with Huntington’s disease 
bind to the PGC-1α promoter and prevent its transcription and the transcription of other nuclear 
transcription factors associated with MB, including CREB.292,293 Huntingtin mutations also cause 
impaired mitochondrial calcium handling,294 reduced respiration,295,296 and disrupted 
mitochondrial dynamics.297,298 Finally, genetic and toxicant-induced models of Alzheimer disease 
and samples from human patients confirm the suppression of mitochondrial proteins and the MB 
transcriptome in Alzheimer disease,299,300 along with mtDNA damage and disruptions in 
mitophagy and mitochondrial morphology.301-303 Thus, compounds that induce MB may alleviate 
cellular dysfunction associated with acute and chronic degenerative diseases and promote organ 
repair and recovery that leads to improvements in patient health.230 
Natural Products 
Because mitochondria and oxidative stress are associated with aging, populations with 
longer lifespans have been studied to identify a potential means for preventing deleterious effects 
of aging. These studies have identified multiple chemicals capable of inducing MB (Figure 1-5), 
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Figure 1-5. Naturally occurring polyphenols capable of inducing MB. Adapted from Cameron 
R.B. et. al. Development of Therapeutics That Induce Mitochondrial Biogenesis for the 
Treatment of Acute and Chronic Degenerative Diseases. J. Med. Chem. 2016.  
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signaling axes. Nonetheless, their therapeutic applicability in many cases is limited by poor 
absorption and low oral bioavailability. 
Resveratrol  
A widely studied nutritional activator of MB is the polyphenol resveratrol (1).304 
Compound 1 has been shown to induce MB by activating SIRT1 directly or indirectly through 
AMPK.305 SIRT1 in turn deacetylates PGC-1α and allows it to exert its transcriptional effects. In 
particular, 1 activates AMPK by inhibiting components of the electron transport chain such as 
complex I and F1/F0 ATPase.306,307 Docking studies with complex I suggest that resveratrol binds 
to the NAD+ binding site of complex I through pi stacking interactions with its aromatic 
components and by hydrogen bond interactions through its hydroxyl group.307 When binding 
F1/F0 ATPase, 1 prevents rotation of the ATP synthase complex through a network of 
hydrophilic and hydrophobic interactions.306 Compound 1 can also directly activate PPARα via 
interactions with the 4’-hydroxyl group.308 It also activates PPARγ by interactions between R280 
and its 4’-hydroxyl group near the opening of the ligand binding pocket as well as Van der Waals 
interactions with F264, H266, and R288.309 Together, protein-ligand interactions trigger signals 
that induce MB. In models of diabetic cardiovascular disease, 1 induces MB and restores vascular 
reactivity in vitro and in vivo.310 In cellular and animal models of neuronal radiation damage,311 
Alzheimer disease,312 Parkinson disease,313 and Huntington’s disease,314 1  normalizes 
mitochondrial function and rescue cellular viability and function. Compound 1 also attenuates 
oxidative stress in fibroblasts from patients with Complex I deficiency by increasing SOD2 in a 
SIRT3-dependent manner.315 Human clinical trials using 1 demonstrated improved lipid profiles, 
antioxidant defenses, and vascular reactivity in diabetic and obese subjects;316-321 however, there 
are conflicting data regarding the effect of 1 on insulin sensitivity,316,320,322 and 1 had no effect in 




(-)-Epicatechin (2),324 primarily found in cocoa, has been shown to induce MB through 
multiple signaling pathways, including Akt-dependent nitric oxide (NO) generation,325,326 CREB 
phosphorylation, and δ-opioid receptor activation.327 The epicatechin epigallocatechin-3-gallate 
(3),328 promotes cAMP-dependent signaling to increase SIRT1 and PGC-1α.329 Although there 
are limited data regarding the structural basis for 2 activation of cAMP-dependent signaling, Akt-
dependent signaling is mediated by the 3”-, 3’-, and 4’-hydroxyl groups.330 Following oxygen-
glucose deprivation, neuronal viability is rescued by 2 via the Akt-eNOS pathway and CREB 
activation.326 In a mouse model of diabetes, 2 reduces oxidative stress in cardiac tissue by 
inducing MB.331 Similarly, in mouse models of cardiovascular disease, 2 acts through the δ-
opioid receptor to prevent mitochondrial swelling and to increase respiration;327,332 it can also 
decrease cardiac ischemia-reperfusion injury through NO and cGMP generation. Even in aged 
mice, epicatechin increases expression of mitochondrial and antioxidant proteins.333 Through its 
cAMP-dependent activation of SIRT1 and PGC-1α, 3 enhances MB in Down’s syndrome patient 
fibroblasts and enhances mitochondrial calcium handling by modulating mitochondrial tethering 
to the rough endoplasmic reticulum.329 Compound 2 also induces MB in human diabetic patients 
to improve skeletal muscle metabolism.334 
Curcumin 
Curcumin (4),335 a diarylheptanoid found in turmeric, has shown promise for promoting 
MB and improved function in several disease models. By activating multiple signaling molecules, 
including p38, PKA, AMPK, SIRT1, and NRF2, 4 can induce MB and protect cells against 
injury.336-338 The o-methoxy group in compound 4 is important for increasing p38-mediated HO-1 
expression, which confers cytoprotection in endothelial cells.336 The unsubstituted 5’- and 5’’-
positions and its olefinic system allow 4 to inhibit NF-κB and activate the NRF2 pathway.339 In 
cellular models of metabolic syndrome, 4 rescues hepatic mtDNA, NRF1, and TFAM and 
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reduces inflammation and NFκB activity.340 In white adipose tissue, 4 increases browning and 
markers of MB via increases in norepinephrine and β3 adrenergic receptor expression.341 
Pretreatment with 4 improves mitochondrial membrane potential, oxygen consumption rates, and 
survival in cellular models of Parkinson disease.342 Compound 4 attenuates neuronal death and 
reduces infarct size following cerebral ischemia-reperfusion injury with concomitant increases in 
mitochondria and improvements in neurological function.343 In animal models of metabolic 
syndrome, 4 restores hepatocyte mitochondrial function to reduce hepatosteatosis.344 Following 
gentamicin-induced nephrotoxicity, 4 can increase PGC-1α and NRF2, thereby elevating 
mitochondrial protein expression and improving mitochondrial structure.337 In rat skeletal muscle, 
4 increases mtDNA content and mitochondrial protein expression following endurance training 
via PKA-dependent activation of AMPK, SIRT1, and PGC-1α.338  
Phytoestrogens 
Phytoestrogens, such as genistein (5),345 daidzein (6),346 pyrroloquinoline quinone (7),347 
coumestrol (8),348 and equol (9),349 are natural products often found in legumes such as soybeans. 
They have been shown to exert their effects in part by modulation of estrogen receptors and partly 
via activation of SIRT1.350-352 5-hydroxyl groups prevent SIRT1 activation, whereas 7-hydroxyl 
groups are necessary for SIRT1 activation. Similarly, a 3-phenyl group appears to drive increased 
SIRT1 expression.352 Compounds 5-8 have been shown to induce MB in vitro.352-354 Additionally, 
through their biogenic effects, 5 and 6 rescued cultured RPTC  from oxidant injury.352 In vivo, 5 
and 9 induce MB to improve bioenergetics in ovariectomized mice.355,356 Both 5 and 6 increase 
mitochondrial markers with associated improvements in insulin sensitivity and glucose 
metabolism in diabetic mice.357,358 Compound 5 also reduces the size of a myocardial infarct in 
mice by rescuing mitochondrial function.350 Finally, 7 stimulates MB in both wild type mice and 
transgenic models of Alzheimer disease;359,360 in the latter model, improvements in synaptosomal 
bioenergetics are correlated with cognitive improvement. 
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Transcription Factor Modulators 
Although natural products have been useful in identifying biological targets for MB, their 
poor pharmacokinetic parameters limit their therapeutic potential. Modulators of the 
transcriptional machinery responsible for MB can potently and efficaciously induce MB; 
however, because they activate transcriptional programs other than MB, these compounds can 
have severe side effects that limit their clinical utility.  
Thiazolidinediones 
The thiazolidinediones (TZDs) are a class of hypoglycemic drugs used to treat diabetes 
mellitus that includes rosiglitazone (10),361 pioglitazone (11),362 troglitazone (12),363 and 
ciglitazone (13) (Figure 1-6).364 Classically, they act as agonists of the transcription factor 
peroxisome PPARγ, leading to increased insulin sensitivity. These effects are primarily mediated 
by the acidic head group, which engages in necessary hydrogen bonding interactions with PPARγ 
to stabilize its active conformation.365,366 More recently, acute PPARγ-independent effects of 
TZDs have been discovered, including inhibition of the electron transport chain, which reduces 
the ATP/AMP ratio, leading to AMPK activation and subsequent MB.367-369 TZDs have also been 
shown to exert anti-inflammatory effects and to upregulate the mitochondrial stress-response, 
leading to increased anti-oxidant defenses.367 Although they upregulate multiple signaling 
pathways, the capacity of TZDs to sensitize tissues to the effects of insulin has been shown to 
correlate with increased expression of mitochondrial proteins, suggesting that induction of MB 
may be central to the clinical efficacy of these drugs.370 In vitro, 10-13 increase cell viability and 
improve neuronal function in models of ischemic injury,371 Alzheimer disease,372 Huntington’s 
disease,373,374 and multiple sclerosis.375 Similarly, in animal models of neurodegenerative diseases, 
10 and 11 improve both cellular and behavioral markers of neurological function.376,377 In animal 
models of cardiac disease, 10 can rescue cardiac increases cardiac ROS and can be 

























Ciglitazone, 13  
Figure 1-6. Thiazolidinedione inducers of MB. Adapted from Cameron R.B. et. al. Development 
of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic 
Degenerative Diseases. J. Med. Chem. 2016. 
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pancreatic beta cells,381 and skeletal muscle369,382 to enhance insulin sensitivity. In humans, 11 
induces MB in subcutaneous adipose tissue,383 and 10 can do so in skeletal muscle.384 
Estrogens 
To understand the underlying processes responsible for sex-dependent differences in lifespan and 
oxidative stress, multiple groups reported that estrogens can be protective in various tissues. 
Furthermore, reduced levels of estrogens, such as in ovariectomized mice, lead to increased ROS 
production.385 Estrogens (Figure 1-7) can bind to the transcription factors estrogen receptor α 
(ERα) and estrogen receptor β (ERβ) to directly influence gene expression. 17β-Estradiol (14)386 
and progesterone (15)387 are the principle biologically active estrogens. 14 and 15 interact with 
nuclear estrogen receptors by hydrogen bonding interactions between the ligands’ hydroxyl 
groups and the receptors’ polar residues and by hydrophobic interactions with the receptors’ 
binding pockets.388 ERα-selectivity, such as by the selective ligand 4,4',4''-(4-propyl-[1H]-
pyrazole-1,3,5-triyl)trisphenol (16),389 is mediated by steric bulk to interact with a residue found 
in ERα but not ERβ.389 Selectivity for ERβ by diarylpropionitrile (17)390 is mediated by phenolic 
groups, while its efficacy is improved by its nitrile group.390 Recently, it has also been shown that 
estrogens activate plasma membrane-bound estrogen receptors such as the G protein-coupled 
estrogen receptor (GPER). The GPER-selective ligand G-1(18)391 is structurally similar to 14 but 
is unable to form hydrogen bonds in the nuclear estrogen receptors;391 however, 18’s acetyl group 
and pseudosymmetry allows engagement of specific residues of the GPER to stabilize the active 
conformation.392,393 Compound 14 has been shown to induce MB in immortalized cell lines and in 
a cellular model of Leber hereditary optic neuropathy, a mitochondrial disease. 394,395 In animal 
models, 14 normalizes ROS production, increases antioxidant defenses, and enhances respiratory 
capacity in the heart and brain.385,396 Furthermore, 15 and synthetic estrogen receptor agonists 
such as 16 and 17 have been shown to enhance respiratory capacity in the brain and promote 
































G-1, 18  
Figure 1-7. Estrogen inducers of MB. Adapted from Cameron R.B. et. al. Development of 
Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic 




proteins. Additionally, at least a portion of the cardioprotective effects of estrogen are mediated 
through the GPER, as shown by stimulation with the GPER-selective agonist 18.385 Despite the 
clear protective potential of estrogens, their proliferative and endocrine effects limit their use as a 
long-term therapy for chronic degenerative diseases. However, the development of selective ER 
and GPER ligands that drive specific signaling and transcriptional programs may improve the 
utility of such therapeutics. 
SIRT1 activators 
The identification of SIRT1 as a common target of natural product-induced increases in 
PGC-1α led to the development of multiple SIRT1 activators, such as SRT1720 (19),397 SRT1460 
(20),397 SRT2183 (21),397 and SRT2104 (22) (Figure 1-8).398 In the initial synthesis of SIRT1 
activators,399 the basic methylamino ring at C-3 of the imidazothiazole ring of 19 and 20 
enhanced water solubility, while derivatization of the amide group (such as with the 2-
quinoxaline group of 19) improved potency and efficacy. Interestingly, both 19 and 20 share a 
methylamino ring and have greater efficacy, whereas 19 and 21 have a 2-quinoxaline group and 
more potency,397 suggesting that the two groups may play distinct roles in the pharmacodynamic 
qualities of these compounds. The direct mechanisms of action for the sirtuin class have been 
controversial. Assays with isolated fluorescent peptides were used for optimization, but direct 
proteomic assays indicate that 19-21 do not directly activate SIRT1 and, rather, act 
promiscuously to activate or inhibit numerous targets;400 however, other work has shown that 
these compounds directly activate SIRT1 by binding to amino acid E230.401  
Due to numerous SIRT1 targets, these activators can affect various cellular processes, 
including inflammation, lysosomal trafficking, and metabolism. Among its targets, SIRT1 
deacetylates PGC-1α, facilitating nuclear import of and transcriptional regulation by PGC-1α, 
leading to MB. In models of type II diabetes mellitus, SIRT1 activators have been shown to 















































SRT2104, 22  
Figure 1-8. Activators of SIRT1 that induce MB. Adapted from Cameron R.B. et. al. 
Development of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute 
and Chronic Degenerative Diseases. J. Med. Chem. 2016  
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metabolism and increase mitochondrial markers;397,402-404 however, other studies have shown a 
lack of efficacy in diabetic mice, calling into question the beneficial effects of these 
compounds.400 With respect to neurodegenerative diseases, SIRT1 activators prevent 
neurodegeneration and restore MB in animal models of Huntington’s disease and multiple 
sclerosis.405,406 SIRT1 activation has shown promise in renal disease, restoring renal function after 
AKI and preventing renal medullary damage in obstructive nephropathy.233,407,408 In models of 
cardiovascular disease, 19 reduces the size of myocardial infarction and preserves contractility,409 
as well as reducing ROS and improving contractility in mice with enhanced ALDH2 activity.410 
Compound 19 also preserves endothelial function in aged mice.411 Even in healthy animals, 19 
and other SIRT1 activators have been shown to extend lifespan and “healthspan” by preventing 
the development of age-associated diseases in multiple organ systems.412 In human trials, 22 
improved lipid profiles in diabetic patients but did not affect plasma glucose or insulin, likely due 
to large pharmacokinetic variability.413 Additionally, 22 reduces cholesterol, LDL, and 
triglycerides in otherwise healthy smokers,414 suggesting that SIRT1 activation is important to the 
human healthspan. 
Kinase Modulators 
Kinases either phosphorylate target proteins or function as scaffolds to co-localize other 
kinases and targets to regulate cellular signaling. Phosphorylation of specific targets can either 
activate or inhibit cellular signaling pathways in response to environmental cues. Because they 
are central signaling molecules, kinases are attractive therapeutic targets. In particular, activators 
of kinases that induce MB, such as AMPK, can be useful in multiple diseases. Unfortunately, 
inhibitors are easier to develop, and most kinase modulators are inhibitors. However, inhibitors of 
kinases that negatively regulate MB, such as extracellular signal-regulated kinases 1/2 (ERK1/2), 




AMPK is an energy sensing kinase involved in the modulation of metabolism through the 
cellular AMP/ATP ratio. AMPK activation is increased during exercise and induces MB, and it is 
decreased with aging and during multiple chronic degenerative diseases.415 AMPK activation has 
been shown to be an upstream regulator of sirtuins and therefore PGC-1α.416 Furthermore, 
pharmacologic activation of AMPK has been observed with multiple natural products that induce 
MB. Activators of AMPK (Figure 1-9), including the indirect activators AICAR (23),417 
metformin (24),418 phenformin (25),419 R419 (26),420 and C24 (27),421 and the direct activator 
A769662 (28),422 have been developed and induce MB in multiple cell lines. Additionally, 23 has 
been shown to enhance proliferation and increase ATP in models of complex I deficiency and 
MELAS.423,424 Compound 23 is biotransformed via phosphorylation within the cell and acts as an 
AMP mimetic to activate AMPK and other AMP-dependent processes.417 The biguanides 24 and 
25 activate AMPK in a LKB1-dependent manner and through inhibition of complex I;420,425 by 
inhibiting the electron transport chain, the AMP/ATP ratio is increased, leading to AMPK 
activation. Compound 26 also indirectly activates AMPK via complex I inhibition,420 and 28 
activates AMPK by binding to an allosteric site between the alpha and beta subunits of AMPK. 
28 both allosterically activates and prevents Thr172 dephosphorylation.426  
In models of diabetes and metabolic syndrome, 23 mimics high intensity exercise in 
skeletal muscle with accompanying increases in SIRT1 activation and PGC-1α activity. These 
improvements in MB decrease oxidative stress in both renal and endothelial cells,427-429 
preventing common comorbidities such as diabetic nephropathy and poor wound healing. 
Compound 23 can also improve pancreatic morphology via AMPK activation to enhance insulin 
sensitivity and GLUT4 expression,430 thereby decreasing plasma glucose. In hepatic cells, 27 





































































JTP-70902, 31  
Figure 1-9. Kinase modulators that induce MB. Adapted from Cameron R.B. et. al. Development 
of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic 
Degenerative Diseases. J. Med. Chem. 2016. 
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function.421 In humans with gestational or type II diabetes, 23 and 25 prevents insulin resistance 
in multiple tissues.431-433 In the heart, 23 reduces oxidative stress and improves contractility,434 
and it is associated with improvements in insulin sensitivity in diabetic mice as well as reductions 
in cold ischemic injury in mouse models of heart transplant.435 
AMPK activators have also shown promise for treating neurodegenerative diseases. 
Neuronal activity has been shown to drive PGC-1α and NRF-1 expression in an AMPK-
dependent manner,436 leading to MB, and pharmacologic activation of AMPK has been shown to 
mimic these effects. Compound 23 has also been shown to impact neuronal development by 
promoting mitochondrial accumulation at axonal branch points, thereby facilitating branch 
formation and retention.437 In models of Alzheimer disease, 23 ameliorated mitochondrial 
dysfunction and prevented neurotoxicity and tau hyperphosphorylation.438,439 Compound 23 
decreased amyloid beta, a protein implicated in Alzheimer disease, in a PPARγ dependent 
manner.440 Compound 23 has also been shown to decrease inflammation in models of multiple 
sclerosis, attenuating pathological and behavioral changes. Furthermore, in models of ischemic 
brain injury, 23 diminishes ischemic neuronal damage.441 
ERK1/2 
Another means of inducing MB is the inhibition of negative regulators of MB, such as 
ERK1/2. Following its activation by MEK1/2, ERK1/2 regulates a variety of cellular processes, 
including differentiation, apoptosis, survival, proliferation, and motility.442 Inhibition of MEK by 
U0126 (29)443 or trametinib (30)444 leads to a rapid suppression of ERK1/2 phosphorylation 
(Figure 1-9). Compound 29 can exist in the (Z,Z) or (Z,E) isomer; however, the (Z,Z) isomer 
provides better MEK inhibition, as does the presence of electron donating amino groups at o-
positions of its phenyl groups.443 The iodo- and cyclopropyl groups of Compound 30 improve 
potency for cancer cell growth inhibitory activity over its lead compound JTP-70902 (31)444, 
while its methyl groups improve stability and its acetamide group improves solubility.444 ERK1/2 
42 
has been shown to suppress PGC-1α in melanoma cells.445 Additionally, in models of Parkinson 
disease ERK1/2 activation leads to phosphorylation of TFAM, impairing its ability to bind to 
mitochondrial DNA.446 MEK1/2 inhibitors, such as 29 and 30, have been developed for cancer 
chemotherapy. In vitro models of renal oxidative stress indicate that ERK1/2 is a mediator of 
oxidative damage in proximal tubule cells, and that its inhibition by 29 prevents oxidative 
damage.447 Our laboratory has shown that ERK1/2 activation increases after AKI and that pre-
treatment with the MEK1/2 inhibitor 30 rescues mitochondrial function and restores renal 
function in a mouse model of AKI.206 These data indicate that inhibition of suppressors of MB 
can induce MB and restore organ function following injury.  
Cyclic Nucleotide Modulators 
The cyclic nucleotides cGMP and cAMP are cellular second messengers that are 
generated in response to extracellular signals. They activate downstream kinases or are 
hydrolyzed by phosphodiesterases (PDE). NO increases cGMP synthesis by binding to a heme 
group on soluble guanylate cyclase (sGC), while cAMP is increased through activation of 
adenylate cyclase by the stimulatory G-protein Gαs. Because cyclic nucleotide generation is 
disrupted in multiple pathological states, cyclic nucleotide modulators are attractive targeted 
therapies for the induction of MB in various diseases. 
NO-cGMP-PKG Axis 
The NO-cGMP-PKG pathway can be modulated by: 1) nitric oxide (NO) donors, such as 
sodium nitroprusside (32), (+)S-nitroso-N-acetylpenicillamine (SNAP, 33),448 diethylamine 
NONOate (DEA-NONOate, 34),449 and diethylenetriamine-NONOate (DETA-NONOate, 35)449 
which increase cellular NO (Figure 8); 2)  sGC stimulators and activators, such as cinaciguat 
(36),450 riociguat (37),451 and BAY 41-2272 (38)452 which directly increase cGMP production 
(Figure 1-10); and 3) phosphodiesterase (PDE) inhibitors, such as zaprinast (39),453 sildenafil 
(40),454 udenafil (41),455 tadalafil (42),456 and vardenafil (43)457 which increase cGMP by 
43 
preventing its hydrolysis (Figure 1-10). Clinically, these compounds are used to induce 
vasodilation to treat hypertension or erectile dysfunction. Activation of this pathway has been 
shown to increase PGC-1α and stimulate MB both through the activation of PKG and 
nitrosylation of transcription factors to increase their binding to the PGC-1α promoter.458,459  
As their name implies, all NO donors have a group, usually a nitrate or a furoxan group, 
that can be liberated to form NO. Because the NO donating group is small, NO donors can be 
“fine-tuned” for multiple clinical uses and to slow the rate of NO release.460,461 However, because 
NO generation causes such a dramatic drop in blood pressure, NO donors are of limited clinical 
use. However, these compounds readily confirm the importance of NO for preventing metabolic 
derangements and cell death, particularly in skeletal muscle. In hypoxia, dietary nitrate (a natural 
NO donor) prevents PGC-1α suppression, leading to increases in fatty acid oxidation and 
respiration. Even under normoxic conditions, nitrate stimulates MB in a cGMP/PKG-dependent 
manner.462 Compound 33 has also been shown to induce MB in myoblasts and reduce the effects 
of caspase-dependent and –independent apoptotic molecules,463 and 34 also improves synaptic 
conduction in models of Alzheimer disease in a cGMP-dependent manner.464 sGC activators and 
stimulators increase the activity of sGC in the absence of NO. Stimulators such as 37 and 38 
increase sGC activity with a non-oxidized heme group, whereas activators increase sGC activity 
even if the heme prosthetic group is oxidized. Both classes of compounds have been approved for 
clinical use to treat pulmonary hypertension. Compound 38 was optimized for vasorelaxation 
through the addition of a 2-fluoro-phenyl group, a pyrazolo[3,4-b]pyridine ring, and a 
cyclopropyl group.452 Compound 37 was optimized to increase oral bioavailability and half-life, 
and to reduce clearance via amino and N-methylcarbamate substitutions on the pyrimidine 
group.451 On the other hand, sGC activators have shown greater utility beyond blood pressure 
control, likely due to their capacity to activate sGC even under high oxidative stress. Compound 

























































Figure 1-10. Activators and stimulators of the NO/cGMP pathway. Adapted from Cameron R.B. 
et. al. Development of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of 
Acute and Chronic Degenerative Diseases. J. Med. Chem. 2016. 
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by interacting with its YXSXR motif through carboxylic acid moieties.465 In pre-clinical studies, 
compounds 36-38 improve cardiac, renal, and neurological function across multiple disease 
models including ischemia reperfusion injury, sepsis, diabetes, and Alzheimer disease.466-470 
However, despite the efficacy of cGMP in promoting MB, few studies have examined the role of 
MB in these functional improvements. Compound 36 protects against myocardial infarction by 
increasing H2S, a known inducer of MB,471 suggesting that further investigation is warranted into 
the role of MB in these compounds’ protective effects.  
Inhibition of cGMP-selective PDEs prevents cGMP hydrolysis, promoting its 
accumulation in the cell and facilitating stimulation of MB. Compound 40 was designed from 39 
by mimicking the guanosine dipole moment, adding an ethoxy group to improve potency, and 
adding a piperazine sulfonamide to improve solubility, selectivity, and potency.472 However, both 
40 and 41 discriminate poorly between PDE5 and PDE6, leading to visual side effects.455 
Compound 42 has better selectivity for PDE5 over PDE6 with the addition of more electron 
donating groups; however, relative to 40 and 43, 42 is less selective for PDE11.456,473,474 Although 
these compounds have been extensively developed for treating pulmonary hypertension and 
erectile dysfunction, they also have been tested for treating other diseases as described below.  
Because cGMP-selective PDE inhibitors were designed to reduce blood pressure via 
increased vasodilation, it is reasonable that they have been tested for conditions characterized by 
endothelial dysfunction, such as diabetes. As expected, in models of diabetes, 40 improves 
endothelial function as measured by flow-mediated dilation.475,476 In addition to their effects on 
vascular reactivity, 40, 42, and 43 reduce plasma markers of diabetes, such as lipids, serum 
glucose, and HbA1c, and are associated with improvements in mitochondrial content.477-480 In 
adipocytes and hepatocytes, 40 enhances lipid oxidation and increases insulin tolerance and 
cellular morphology.477 cGMP-selective PDE inhibitors also reduce diabetic complications in 
other organs, such as the kidney and heart. In models of diabetic nephropathy, 40 reduces 
46 
microalbuminuria, a predictor of renal and cardiac dysfunction.478 Additionally, in diabetic mice, 
42 rescues the expression of cardiac cytoskeletal and redox proteins to improve cardiac 
morphology and function.480,481 
In addition to beneficial reductions in the development of diabetic cardiomyopathy, 
cGMP-selective PDE inhibitors also ameliorate non-diabetic cardiac dysfunction. In ischemic 
cardiomyopathy and myocardial infarction, 40, 42, and 43 increase survival and decrease infarct 
size by reducing cell death and preserving mitochondrial function.482-484 Compound 42 also 
prevents cardiac remodeling and hypertrophy, stabilizing contractility rather than allowing 
progression to heart failure and pulmonary edema.485 Similarly, in models of mitral regurgitation 
and doxorubicin toxicity, 40 inhibits cell death and preserves mitochondrial function by 
upregulating anti-apoptotic proteins and maintaining the mitochondrial membrane potential.486,487 
cAMP-PKA-CREB axis 
CREB regulates PGC-1α activity and expression to promote MB and is down-regulated 
in multiple disease states characterized by mitochondrial dysfunction. In Alzheimer disease, 
CREB phosphorylation is diminished due to impaired activation by PKA. This loss of activity 
leads to a downregulation of PGC-1α and an imbalance in tau protein, a driver of Alzheimer 
disease.488 A similar decrease in CREB activity has been observed in Huntington’s disease.489 
Additionally, ethanol decreases cellular cAMP, thereby reducing CREB activity to suppress 
PGC-1α and thereby exert its toxic effects.490 Taken together, these data indicate that activation 
of the cAMP-PKA-CREB signaling pathway can promote MB and protect against 
neurodegenerative diseases. 
The primary therapeutic approach for activating this signaling axis is with 
phosphodiesterase (PDE) inhibitors such as rolipram (44)491 and cilostazol (45)492 (Figure 1-11). 
Compound 44 inhibits PDE4, a cAMP-selective PDE, whereas 45 inhibits PDE3, a PDE capable 







































































Figure 1-11. Phosphodiesterase (PDE) inhibitors associated with MB. Adapted from Cameron 
R.B. et. al. Development of Therapeutics That Induce Mitochondrial Biogenesis for the 




than that of cGMP. Compound 44’s selectivity arises in part from its optimized potency for PDE4 
and the unfavorable orientation of a conserved glutamate residue in other PDEs.493 In contrast, the 
lactam group of 45 engages in hydrogen bonding interactions with multiple receptor residues to 
promote PDE3 selectivity.494 Both 44 and 45 can increase PGC-1α in vitro, indicating that they 
induce MB,495 and both have shown potential for therapeutic use in pre-clinical disease models.  
However, in humans, 44’s narrow therapeutic window limits its application, whereas 45 is 
approved for clinical use in the treatment of diabetic vascular complications. 
Restoration of the cAMP-PKA-CREB pathway substantially reduces the effects of 
neurodegenerative diseases. In animal models of Huntington’s disease, 44 improves neuronal 
function, morphology, and survival and decreases neurological impairment.489,496 Compound 44 
also reduces synaptic conduction abnormalities associated with Alzheimer disease, improving 
cognition.497,498 These effects and increased CREB phosphorylation lasted beyond the cessation of 
treatment. In ischemic brain injury, 45 reduces neuroinflammation, reducing infarction size and 
decreasing apoptosis and free radical production.499,500 In models of Alzheimer disease, 45 
increases SIRT1 expression, reducing symptoms and improving cognitition.501 Furthermore, in a 
retrospective study, 45 improved cognition in human patients,502 suggesting that PDE3 inhibition 
holds promise for treating Alzheimer disease. Used clinically to treat claudication, the beneficial 
effects of 45 in models of diabetic cardiovascular disease are well studied. In models of limb 
ischemia, 45 increases angiogenesis by rescuing PPARγ, increasing angiogenic factors vascular 
endothelial growth factor (VEGF) and hepatocyte growth factor (HGF);503,504 this normalization 
of PPARγ also occurs in other tissues, such as the retina and the kidney.505 Compound 45 also 
prevents endothelial cell senescence by increasing cAMP, leading to SIRT1 activation. In the 
heart, 45 reduces oxidant-induced mitochondrial dysfunction and significantly reduces 
myocardial infarction size.506-508 Furthermore, 45 improves insulin sensitivity and reduces blood  
49 
glucose and HbA1c in diabetic mice and human subjects,509-511 as well as reducing the urinary 
excretion of albumin and renal inflammation, indicating that 45 improves diabetic nephropathy. 
Despite these promising data, controversy exists regarding use of cAMP-selective PDEs in 
chronic degenerative diseases of the liver and kidney. On the one hand, 45 improves hepatic 
function after ischemic insult by inducing MB;512 however, in models of lipotoxicity, increased 
cAMP acts synergistically to induce cell death despite concurrent stimulation of MB.513 
Additionally, despite the promising work in diabetic nephropathy described previously, we found 
that cAMP-selective PDE inhibitors do not induce MB in proximal tubule cells,514 suggesting 
they are poor therapeutic options for treating AKI. 
GPCR Ligands 
G protein-coupled receptors (GPCRs) are well characterized plasma membrane receptors 
that are the target of a substantial portion of currently available drugs. By coupling to G proteins, 
GPCRs can modulate cAMP, calcium, and NO and activate various kinases and signaling 
pathways. Additionally, different ligands of the same receptor can cause activation of distinct 
signaling programs, a phenomenon known as “functional selectivity” or “biased agonism.”515 By 
stabilizing different receptor conformations, different ligands can alter receptor interactions with 
G proteins, G protein-coupled receptor kinases (GRKs), and scaffolding proteins such as 
arrestins. One such scaffolding protein, GRK interacting protein 1 (GIT1), regulates MB in the 
heart, likely in an eNOS-dependent manner.516,517 Biased agonism allows for the development of 
ligands that selectively stimulate signaling pathways that lead to MB while inhibiting negative 
regulators of MB. Many GPCRs are modulated by endogenous molecules, a fact which has 
facilitated the development of potent and selective agonists and antagonists for various receptors. 
Despite the potential of GPCRs to activate pathways known to induce MB and the availability of 
clinically approved GPCR ligands, little investigation has occurred to explore the potential of 
such compounds to induce MB. 
50 
Cannabinoid-1 receptor 
Cannabinoid-1 receptor (CB1R) antagonists such as taranabant (46)518 and rimonobant 
(47)519 were studied for anorectic effects (Figure 1-12). Despite the lack of a cyclic linker, 46 
binds in a similar mode to 47; however, the amide group on 46 is able to engage in an extra 
hydrogen bonding interaction, leading to its enhanced affinity for the CB1R.518,520 By inhibiting 
CB1R activity in the brain, these compounds can suppress appetite and cause weight loss with 
concomitant improvements in plasma lipid profiles.  Both 46 and 47 were efficacious for 
inducing weight loss in wild type mice, mice fed a high fat diet, and ob/ob mice.521,522 Inhibition 
of CB1R by 47 or by genetic ablation induces MB in adipose tissue and MB in a cAMP- and 
eNOS-dependent manner, leading to decreases in body weight and fat content.521 Interestingly, 47 
increased mitochondrial energy production was not correlated with increased  mitochondrial mass 
in rat livers, indicating improved mitochondrial efficiency.523 Although both 46 and 47 were 
efficacious in animal models, investigation of 46 was halted in Phase III trials, and 46 was 
withdrawn from the market in the U.S. after initial approval as an anti-obesity drug. In humans, 
47 reduced food intake and increased energy consumption to promote weight loss but caused 


















Figure 1-12. Cannabinoid-1 Receptor antagonists. Adapted from Cameron R.B. et. al. 
Development of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute 





Endogenous serotonin binds to the 5-hydroxytryptamine (5-HT) class of receptors (48, 
Figure 1-13)526. 5-HT receptors are primarily GPCRs that have been identified as therapeutic 
targets for neuropsychiatric, neurologic, and cardiac diseases. The synthetic ligand alpha-methyl-
5-hydroxytryptamine (49)527 possesses an extra methyl group that prevents its metabolism by 
monoamine oxidase.528 The 5-HT2 receptor agonist DOI (50)529 has enhanced selectivity due to its 
primary amine, with the iodo-group  adding to its potency.530 Much work has been done to 
identify and characterize the pharmacophore of 5-HT2C receptor agonists (e.g., CP809101, 51)531 
and antagonists (e.g. SB242084, 52)532 and optimize their selectivity.530-532 5-HT2C receptor 
agonists stabilize the TM6 domain of the receptor through its aromatic group, whereas 
antagonists interact with Asn331, Val354, and Ser334 through a positively ionizable group.533  
In addition to direct 5-HT receptor antagonists, serotonin reuptake inhibitors such as fluoxetine 
(53)534 prevent the uptake and degradation of 48 and prolong its actions at its receptors. The p-
trifluoromethyl group of 53 confers selectivity for the serotonin reuptake transporter by binding 
to I172 in its transmembrane domain.535,536 Treating rat pups with 53 improves mitochondrial 
membrane potential, respiratory capacity, and antioxidant defense in the heart, implicating 48 in 
mitochondrial health during development.537 
Our laboratory identified multiple ligands that induce MB through various 5-HT 
receptors. In RPTC, we have shown that the non-selective 5-HT receptor agonist 49 induces 
MB.538 The 5-HT2 receptor agonist 50 increased cellular respiration in vitro and improved 
recovery from oxidant injury by tert-butyl hydrogen peroxide (TBHP); interestingly, induction of 
MB did not reduce initial injury by TBHP.539 The 5-HT2C selective ligands 51 and 52 induce MB 
in vitro and in naïve mice; interestingly, siRNA studies and work in knockout mice indicate that 






















































Fluoxetine, 53  
Figure 1-13. 5-Hydroxytryptamine receptor modulators that induce MB. Adapted from Cameron 
R.B. et. al. Development of Therapeutics That Induce Mitochondrial Biogenesis for the 
Treatment of Acute and Chronic Degenerative Diseases. J. Med. Chem. 2016. 
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In contrast to 5-HT2 receptors, the 5-HT1F receptor has few selective ligands-namely, 
LY334370 (54) and LY344864 (55) and limited data regarding its pharmacophore. Nevertheless, 
the selective 5-HT1F agonists 54 and 55 induced MB in vitro, and 55 also improved recovery from 
ischemia-reperfusion-induced AKI in vivo.538 Additionally, preliminary data suggest that 55 
stimulates MB through the Gβγ-dependent activation of Akt and eNOS.541 These data indicate 
that the induction of MB by 5-HT agonists could be clinically useful for treating AKI and other 
acute organ injuries as they effectively promote recovery and regeneration even after initial 
injury. 
Beta adrenergic receptors 
The beta adrenergic receptor family is activated by endogenous stress hormones 
epinephrine (56)542 and norepinephrine (57, Figure 1-14)542 and the family comprises three 
receptors. First, the beta-1 adrenergic receptor, primarily expressed in the heart, is targeted by 
drugs that affect cardiac contractility and heart rate. The beta-2 adrenergic receptor (β2AR), 
which is ubiquitously expressed, is a target of bronchodilators to treat asthma and COPD. The 
beta-3 adrenergic receptor, which is primarily expressed in adipose tissue and the urinary bladder 
and is targeted to treat overactive bladder.543  
Beta-adrenergic agonists contain distinct structural features, specifically a catechol or 
phenethanolamine core, whereas antagonists have a 3-aminophenoxypropan-2-ol core. However, 
while beta-adrenergic agonists have been extensively studied to optimize pharmacodynamics and 
pharmacokinetic parameters, there are few studies relating structural features to the induction of 
MB. Compounds 56, 57, and the non-selective beta adrenergic receptor agonist isoproterenol 
(58)544 increase PGC-1α in brown adipose of  naïve mice and in models of obesity in a cAMP- 
and p62-dependent manner.545 Interestingly, in models of cardiac dysfunction, beta-1 adrenergic 































































Figure 1-14. Beta adrenergic receptor modulators tested for the induction of MB. Adapted from 
Cameron R.B. et. al. Development of Therapeutics That Induce Mitochondrial Biogenesis for the 




blockade by the beta-1 selective antagonist metoprolol (60)548 enhances PGC-1α activation and 
improves cardiac metabolism and function.549,550  
  
57 
Beta-2 Adrenergic Receptors and Mitochondrial Biogenesis 
Our laboratory has studied β2AR selective agonists in renal MB, and the following 
section will discuss the signaling of the β2AR and its known role in the induction of MB. 
The β2AR is a well-studied and well-drugged GPCR. The β2AR is ubiquitously expressed 
and is activated by its endogenous ligand, epinephrine, to induce smooth muscle relaxation in the 
vasculature and airways,551,552 increased glycogenolysis in the liver,553 inhibition of histamine-
release by mast cells,554 and increased insulin secretion from the pancreas.555 More relevant to the 
kidney, the β2AR regulates systemic blood pressure and solute reabsorption by increasing renin 
secretion,556 thereby activating the renin-angiotensin-aldosterone system.  
The β2AR canonically couples to Gαs, leading to an increased accumulation of cAMP 
and subsequent activation of PKA, Epac, and CREB.557 However, the β2AR has also been shown 
to couple to Gαi, which inhibits adenylate cyclase and releases the Gβγ heterodimer, and 
arrestins, which act as scaffolding for other effector molecules. Phosphorylation of the C-terminal 
tail of the receptor by G protein-coupled receptor kinases (GRKs) and other kinases such as PKA 
altered coupling of these effectors. The phosphorylation of the receptor by these kinases can lead 
to a switch from Gαs to Gαi,558 thereby limiting the duration and magnitude of cAMP-dependent 
signaling, or it can lead to the recruitment of β-arrestin,559 which modulates desensitization, 
receptor internalization, or its own signaling program. 
The coupling of these effectors depends on the conformation of the receptor, which, in 
turn, is dependent on the structure of the bound ligand. Thus, different ligands binding to the 
same receptor, either at allosteric or orthosteric sites, can cause differences in downstream 
signaling.560 This phenomenon is known as “functional selectivity” or “biased agonism.” β2AR 
agonists have been shown to be G protein biased (that is, selectively activating G protein-
depending signaling cascades) and arrestin biased (that is, selectively activating an arrestin 
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signaling program).557 In addition to effects on effector coupling to the receptor, biased ligands 
can also impact the signaling properties of the effector molecules. For example, different ligands 
of the calcitonin receptor altered the conformation of the receptor-G protein complex,561 leading 
to differences in cAMP accumulation. A similar phenomenon has been observed for arrestins,562 
with different ligands leading to distinct conformational signatures that inform function.  
A phenotypic screening for compounds that induce MB identified formoterol as a potent 
and efficacious inducer of MB in RPTC. Because the β2AR is so widely drugged, other β2AR 
agonists were screened for their ability to induce MB in RPTC. In particular, formoterol (61),563 
fenoterol (62),564 and procaterol (63)565  induced MB in vitro at pharmacologically relevant 
doses.566,567. However, other β2AR agonists such as clenbuterol (64)568 and isoetharine (65)569did 
not induce MB in vitro,566 suggesting that ligand-directed signaling can be exploited to develop 
more effective mitochondrial biogenic β2AR agonists.  
Beta adrenergic signaling activates PGC-1α and induces MB in multiple tissues. In 
Leydig cells, stress increased steroid hormone production,570 a process involving mitochondrial 
enzymes. This was associated with increased mitochondrial content and the expression of PGC-1 
proteins through cAMP/PKA/CREB, NO/cGMP, and beta adrenergic receptor signaling. In 
mouse skeletal muscle and in human subjects, exercise induced MB in a beta adrenergic receptor-
dependent manner.571,572 While isoproterenol did not affect MB in human skeletal muscle,573 in 
mice the effects on PGC-1α and MB were mimicked by treatment with clenbuterol.571 Both 
exercise and clenbuterol specifically increased the b and c isoforms of PGC-1α in skeletal 
muscle,571 while other environmental inducers (fasting and cold) caused increases in tissue-
specific expression patterns of PGC-1α isoforms.574 The tissue-specific changes in PGC-1α 
isoforms suggest differences in signaling for MB across cell types that would explain differences 
in β2AR agonist efficacy for MB. Consistent with this hypothesis, in rats clenbuterol activated 
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p38 MAP kinase to induce MB in fat but not skeletal muscle, despite activation of CREB in both 
tissues.575 
 Formoterol (61) has been confirmed to induce MB in vivo in naïve mice as well as in 
mice subjected to AKI,231 and this was associated with improvements in renal function, indicating 
that formoterol has therapeutic promise for treating AKI. Because both MB-inducing and non-
MB-inducing β2AR agonists increased cAMP, we suggest that the classical Gαs-signaling 
pathway is not responsible for β2AR-induced MB in the kidney. In addition to its renal effects, 
formoterol inducds MB in multiple other tissues, including the heart and skeletal muscle.567,576 
Together, these data indicate that certain β2AR agonists such as formoterol can be used to treat 
multiple diseases and improve mitochondrial function and ameliorate symptoms. 
Previous studies have explored β2AR activation as a therapeutic target for AKI. In RPTC 
cell lines primarily expressing the β2AR, isoproterenol stimulated proliferation in a cAMP-
dependent manner,577 which would be beneficial following RPTC loss in AKI. Following injury 
by shigatoxin, the β2AR  agonist terbutaline inhibited caspases to prevent apoptosis.578 
Furthermore, overexpression of the β2AR reduced injury and promotes recovery from septic 
AKI,579-581 while blockade of the β2AR worsened septic AKI.582,583 Despite these findings, 
excessive β2AR activation reduced creatinine clearance in rats.584 Together, these studies indicate 
that selective and limited activation of the β2AR is a viable therapeutic strategy for AKI. 
However, the aforementioned studies focused on regulation of proliferation, inflammation and 
apoptosis, particularly in settings of β2AR overexpression. 
Our laboratory sought to determine the role of β2AR activation in a more physiologically 
relevant model of AKI. Mice subjected to bilateral renal ischemia/reperfusion injury developed 
AKI with peak injury at 24 h and a persistent loss of renal function at 144 h.207,231 These mice also 
exhibited persistent suppression of MB and oxidative phosphorylation. Administration of 
60 
formoterol after development of AKI improved renal function and rescued mitochondrial protein 
expression at 144 h.231 However, because the β2AR is ubiquitously expressed, and because 
various cell types mediate the pathogenesis of AKI,194 it was unclear through which cell type(s) 
formoterol exerts its effects. Furthermore, as the β2AR activates numerous signaling pathways, 
and as not all β2AR agonists induced MB, the mechanism by which formoterol induced MB 
remained unclear. 
Our previous studies showed that formoterol induced MB in primary cultures of RPTC,567 
while the selective β2AR agonist clenbuterol did not.566 Therefore, we chose clenbuterol as a 
pharmacologic probe for β2AR signaling that does not induce MB in RPTC. Furthermore, in vivo, 
RPTC injury was sufficient for the development of AKI.178 Therefore, we sought to study the 
effects of formoterol on RPTC and how these effects impact formoterol-induced recovery from 
AKI. We hypothesized that formoterol accelerates recovery of renal function by the induction of 
MB in RPTC and that formoterol does so by activating a signaling pathway distinct from β2AR 
agonists that do not induce MB. We proposed to test this hypothesis through three specific aims: 
1. Identify differences in signaling between formoterol and clenbuterol 
2. Identify the signaling pathway by which formoterol induces MB in RPTC 
3. Determine the role of RPTC in the induction of MB and recovery of renal function by 













CHAPTER 2  
STRUCTURAL AND PHARMACOLOGICAL BASIS FOR THE INDUCTION OF 
MITOCHONDRIAL BIOGENESIS BY FORMOTEROL BUT NOT CLENBUTEROL  
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Introduction 
Mitochondria play numerous roles in cellular homeostasis, including energy metabolism, 
synthesis of key biomolecules, regulation of reactive oxygen species, and apoptosis.236 However, 
in disease states, dysfunctional mitochondria lead to metabolic defects and subsequent 
derangements in survival,585 proliferation,586 and differentiation. 261-263,587 One therapeutic strategy 
to treat mitochondrial dysfunction is the induction of MB.235,588 By generating new mitochondria, 
MB increases cellular respiration and ATP, reduces pathologic oxidative stress, and promotes cell 
repair and regeneration.247,589 
A number of signaling molecules have been shown to induce MB, including transcription 
factors, kinases, cyclic nucleotides, and G protein-coupled receptors (GPCRs).588 In particular, 
GPCRs are attractive targets for the identification of therapeutics that induce MB because GPCRs 
represent numerous clinically approved receptor agonists.590  
Previous work in our laboratory identified formoterol, a β2AR agonist, as a potent and 
efficacious inducer of MB in vitro and in vivo.567 Furthermore, in a mouse model of bilateral 
ischemic reperfusion-induced AKI formoterol stimulated MB with increased mitochondrial 
proteins and accelerated recovery of renal function.231 Based on the success of formoterol, other 
β2AR agonists were screened for induction of MB. Although several agonists were able to induce 
MB similar to formoterol, several other agonists, including clenbuterol, were unable to induce 
MB at any concentration.566 These data suggest that a subset of biogenic β2AR agonists 
modulates distinct signaling pathways from non-biogenic β2AR agonists to induce MB. 
Because both formoterol and clenbuterol, a non MB inducer, are selective β2AR 
agonists,591 we sought to identify the differences in signaling between the two agonists in primary 
cultures of RPTC and the signaling pathway responsible for formoterol-induced MB. 
Furthermore, we explored their chemical differences to identify key functional groups and 
structural differences that result in their differing abilities to induce MB. We found that 
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formoterol, but not clenbuterol, activates the Gβγ-Akt-eNOS-sGC signaling pathway and that this 
pathway is necessary for the transcriptional and functional changes associated with formoterol-
induced MB.  Molecular modeling showed that formoterol stretches further across the binding 
pocket than clenbuterol, allowing for simultaneous interactions with TM3, TM5, and ECL2. 
Additionally, the methoxyphenyl and formamide groups displayed distinct interaction fingerprints 
with the β2AR that may lead to the activation of Gβγ-dependent signaling.  
Results 
Both formoterol and clenbuterol increase cAMP accumulation. The β2AR couples to the 
stimulatory G protein Gαs and the inhibitory G-protein Gαi, both of which affect the activity of 
adenylate cyclase and therefore the accumulation of cAMP. To assess the effects of formoterol 
and clenbuterol on cAMP accumulation, RPTC were co-treated for 1 h with  30 nM formoterol or 
30 nM clenbuterol in the presence of 100 μM IBMX, a phosphodiesterase inhibitor to prevent 
cyclic nucleotide degradation. These concentrations ensure selective activation of the β2AR while 
also exerting the previously observed effects on MB. Maximal cAMP accumulation occurs at 1 h 
(data not shown).566 Both formoterol and clenbuterol increased cAMP relative to vehicle controls 
(Figure 2-1A). Because there was no difference in cAMP accumulation between the two 
compounds, and previous work showed that cAMP does not produce MB in RPTC, we concluded 
that β2AR is functioning normally in RPTC with respect to cAMP production but that cAMP is 


























































































































Figure 2-1. Formoterol and clenbuterol increase cAMP (A, N=3) but only formoterol increases 
cGMP (B, N=6) in RPTC. Levels of cAMP/cGMP were measured 1 h following treatment with 
formoterol or clenbuterol. Mean + SEM. *p<0.05, Wilcoxon signed rank test. 
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Formoterol, but not clenbuterol, increases Akt phosphorylation in a Gβγ-PI3K-dependent 
manner. In addition to their roles in the modulation of cAMP, both Gαs and Gαi release the Gβγ 
heterodimer. To assess the role of Gβγ, we measured Akt phosphorylation 30 min following 
treatment with formoterol or clenbuterol. This time point represents the earliest time point at 
which elevated Akt phosphorylation could be detected (data not shown). Formoterol increased 
Akt phosphorylation while clenbuterol did not (Figure 2-2). Pretreatment with the Gβγ inhibitor 
gallein592 attenuated formoterol-induced Akt phosphorylation (Figure 2-2A), as did pretreatment 
with the phosphatidylinositol-4,5-biphosphate 3-kinase (PI3K) inhibitor LY294002 (Figure 
2-2B).593 These data indicate that formoterol, but not clenbuterol, increases Akt phosphorylation 
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Figure 2-2. Formoterol, but not clenbuterol, activates Akt in a Gβγ-PI3K-dependent manner in 
RPTC. pAkt was measured following 30 min of formoterol (Form) or clenbuterol (Clen) in the 
presence and absence of the Gβγ inhibitor gallein (Gal)(A, N=4) or the PI3K inhibitor LY294002 
(LY)(B, N=4-5). Mean + SEM. *p<0.05 vs. DMSO, #p<0.05 vs. formoterol, one-way ANOVA 
with Sidak’s multiple comparison test. 
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Formoterol, but not clenbuterol, increases eNOS phosphorylation in a Gβγ-Akt-dependent 
manner. Among the downstream targets of Akt is endothelial nitric oxide synthase (eNOS).594 
Upon phosphorylation at S1177, eNOS is activated and increases NO generation. Because NO 
and NO-dependent signaling have been implicated in MB, we treated RPTC with formoterol and 
clenbuterol for 1 h to determine differences in eNOS phosphorylation. Formoterol increased 
eNOS phosphorylation relative to vehicle control, while clenbuterol did not affect eNOS 
phosphorylation (Figure 2-3A). 
To determine the role of the Gβγ-Akt pathway in formoterol-induced eNOS 
phosphorylation, RPTC were pretreated with the Gβγ inhibitor gallein or the Akt inhibitor 
MK2206 followed by treatment with formoterol for 1 h. The allosteric Akt inhibitor MK2206 was 
used because it decreases Akt phosphorylation, thereby confirming that sufficient Akt inhibition 
had occurred.595 Both gallein and MK2206 attenuated formoterol-induced eNOS phosphorylation 
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Figure 2-3. Formoterol (Form), but not clenbuterol (Clen), activates eNOS in a Gβγ- and Akt-
dependent manner in RPTC. (A) p-eNOS was measured following 1 h of formoterol or 
clenbuterol. N=5-6. (B) Phosphorylation of eNOS was measured following 30 min of treatment 
with formoterol in the presence or absence of the Gβγ inhibitor gallein (Gal) or the Akt inhibitor 
MK2206 (MK). N=7-10. Mean + SEM. *p<0.05 vs. DMSO, #p<0.05 vs formoterol, one-way 
ANOVA with Sidak’s multiple comparison test. 
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Formoterol, but not clenbuterol, increases cGMP accumulation. One of the major targets of NO is 
soluble guanylate cyclase (sGC). To examine any differences in cGMP accumulation, RPTC were 
treated with formoterol or clenbuterol in the presence of 100 μM IBMX for 1 h, and cGMP was 
determined by ELISA. Formoterol, but not clenbuterol, increased levels of cGMP relative to 
vehicle control (Figure 2-3B).  
Formoterol increases maximal respiration in a Gβγ-Akt-NOS-sGC-dependent manner. Having 
shown that formoterol but not clenbuterol activates the Gβγ-Akt-eNOS-sGC pathway, we 
assessed the role of this pathway in formoterol-induced increases in FCCP-OCR, a measure of 
MB. RPTC were pretreated with the Gβγ-inhibitor gallein, the Akt inhibitor GDC0068, the NOS 
inhibitor L-NAME, and the sGC inhibitor ODQ. The orthosteric Akt inhibitor GDC0068 was 
used due to its greater potency and lack of isoform selectivity.596 RPTC were then treated with 
formoterol or clenbuterol for 24 h, and FCCP-OCR consumption was measured. This time point 
was chosen based on previous studies identifying that formoterol induces MB at 24 h.566,567 
Formoterol alone increased FCCP-OCR, in agreement with previous studies (Figure 2-4A).566,567 
Pretreatment with gallein, GDC0068, L-NAME, and ODQ attenuated formoterol-induced 
increases in FCCP-OCR, indicating that formoterol-induced MB occurs in a Gβγ-Akt-NOS-sGC-
dependent manner.  Clenbuterol had no effect on FCCP-OCR. 
Formoterol, but not clenbuterol, increases mRNA expression of PGC-1α and NDUFS1 in a Gβγ-
Akt-NOS-sGC-dependent manner. MB requires the integrated transcription of multiple genes. To 
assess the effects of the Gβγ-Akt-eNOS-sGC pathway on the expression of genes associated with 
MB, RPTC were pretreated with gallein, GDC0068, L-NAME, and ODQ, followed by treatment 
with formoterol or clenbuterol for 24 h. RNA expression of PGC-1α and NADH-ubiquinone 
oxidoreductase core subunit S1 (NDUFS1) was assessed using RT-qPCR. Formoterol alone 
caused a small but significant increase in PGC-1α and NDUFS1 (Figure 2-4B, C), which was 
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attenuated by pretreatment with gallein, GDC0068, L-NAME, and ODQ. These data indicate that 
formoterol also increases transcriptional markers of MB in a Gβγ-Akt-NOS-sGC-dependent 
manner. Importantly, clenbuterol did not increase the mRNA expression of PGC-1α or NDUFS1. 
These data were further confirmed by measuring mtDNA copy number, where formoterol, but not 







































































































































































































































































































































































































































Figure 2-4. Formoterol, but not clenbuterol, induces MB in a Gβγ-Akt-NOS-sGC-dependent 
manner. (A) FCCP-OCR (N=3-9), (B) PGC1α mRNA (N=3-10), and (C) NDUFS1 mRNA (N=4-
10) expression was measured 24 h following treatment with formoterol in the presence or absence 
of the Gβγ inhibitor gallein, the Akt inhibitor GDC0068, the NOS inhibitor L-NAME, and the 
sGC inhibitor ODQ. Mean + SEM. *p<0.05 vs DMSO, #p<0.05 vs. Formoterol, one-way 




























































Figure 2-5. Formoterol, but not clenbuterol, increases mtDNA copy number. RPTC were treated 
with 30 nM formoterol or 30 nM clenbuterol for 24 h. DNA was isolated, and copy number of 
ND6 was measured by qPCR. N=4, *-p<0.05, Mann-Whitney test. 
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Formoterol and clenbuterol have distinct interaction fingerprints with the β2AR. Due to the 
differences in signaling described above, we investigated differences in interactions of β2AR 
agonists with the receptor. In addition to formoterol and clenbuterol, other ligands with known 
efficacy for MB were considered, including fenoterol, ritodrine, and terbutaline.566 Ligands were 
docked to three inactive structures of the β2AR (3NYA, 3NY8, 5D5B) and three active structures 
of the β2AR (4LDE, 4LDL, 4LDO).  Due to its longer methoxyphenyl group, formoterol was able 
to extend across the binding pocket to be in proximity to TM2, TM3, ECL2, and TM5 compared 
to clenbuterol (Figure 2-6A). 
  To investigate the interactions of formoterol and clenbuterol with the β2AR with respect 
to distinct structural features, functional groups of the ligands were combined to form 11 
structural features F1-F11 (Figure 2-7), with the catecholamine pharmacophore represented by 
F1-F7 and the tail group represented by F8-F11. For each conformation generated by the docking 
simulations, all interactions between the receptor and the ligand were tabulated. Interactions 
between the ligand and each receptor amino acid were separated by residue, ligand feature, and 
type [i.e., contact (C), arene (R), hydrogen bond donor (D), hydrogen bond acceptor (A), and 
ionic (I)]. Interactions at each of the 11 structural features were added for all generated 
conformations. To identify interactions specific to biogenic β2AR agonists, the interactions of the 
compound with less efficacy for MB were subtracted from those of the compound with greater 
efficacy for MB (e.g., ΣInteractionsFormoterol-ΣInteractionsClenbuterol). The resulting values were used 
to generate a heatmap for the interactions between the receptor and specific structural features of 
the ligand. Interaction pairs with more positive values (blue) indicated a greater importance for 
β2AR-mediated MB (Figure 2-6B).  Interaction pairs with more negative values (orange) indicate 




Figure 2-6. Formoterol and clenbuterol have distinct interaction fingerprints with the β2AR. A. 
Representative poses of formoterol and clenbuterol in the 4LDO crystal structure. Formoterol’s 
methoxyphenyl group (top) allows it to extend further across the binding pocket than clenbuterol 
(bottom), allowing formoterol to simultaneously interact with TM3, TM5, and ECL2. B. 
Formoterol and clenbuterol were docked to inactive structures (3NYA, 3NY8, 5D5B) and active 
structures (4LDE, 4LDL, 4LDO) of the β2AR. From the top 30 poses, ligand interactions were 
matched with structural features F1-F11 and added for each crystal structure. More negative 
(orange) values correspond to a greater number of interactions with clenbuterol, while more 
positive (blue) values correspond to a greater number of interactions with formoterol. Interactions 
are displayed as Residue-interaction type (D- hydrogen bond donor, DD- strong hydrogen bond 
donor, I- ionic, II- strong ionic, A- hydrogen bond acceptor, AA- strong hydrogen bond acceptor, 
C- contact, R- arene, RR- strong arene). Residues followed by a b (e.g., G90b) indicate an 





Figure 2-7. Dividing β2AR agonists into chemical groups reveals distinct structural features. 
Formoterol, clenbuterol, (R,R’)-fenoterol, (S,R’)-fenoterol, ritodrine, and terbutaline were divided 




analysis enables the identification of features of both the ligand and the receptor that distinguish 
biogenic and non-biogenic β2AR agonists. 
As expected for two β2AR agonists with a shared pharmacophore, most of the 
interactions showed only minor preference for formoterol or clenbuterol, with several interactions 
occurring with the same frequency (Figure 2-6B). Interactions between the backbone of C191 and 
F1 were more common for formoterol than clenbuterol, while the reverse was true for F2. 
Interestingly, interactions with both V114 and F193 were more common for clenbuterol over 
features F3-F10; however, at F11, interactions with V114 and F193 more commonly occurred 
with formoterol than clenbuterol. These data reveal a common pharmacophore and marked 
differences in the binding of formoterol and clenbuterol to the β2AR crystal structure and suggest 
that interactions between distinct β2AR residues and distinct ligand structural features must occur 
to activate the Gβγ-Akt-eNOS-sGC pathway and induce MB. 
To confirm the importance of the interactions identified above, we repeated the ligand 
interaction analysis for other ligands previously tested for MB. Fenoterol is a β2AR agonist that 
induces MB in a manner similar to formoterol.566 The (R,R’) enantiomer of fenoterol is a Gαs-
biased ligand; however, the (S,R’) enantiomer activates both Gαs and Gαi, potentially enabling it 
to activate Gβγ-dependent signaling pathways like formoterol.597 Comparing (S,R’)-fenoterol to 
(R,R’)-fenoterol showed that the former was more likely to interact with V114 and F193 at F11 
and engage in hydrogen bonding interactions with S203, S207, and the backbone of C191 (Figure 
2-8A). Because these differences are similar to those between formoterol and clenbuterol, these 
data suggest that the (S,R’) enantiomer of fenoterol with a greater capacity to activate Gβγ-
dependent signaling is more capable of inducing MB than the Gαs-biased (R,R’) enantiomer. 
Comparing (S,R’)-fenoterol to clenbuterol showed a similar interaction profile to formoterol vs. 
clenbuterol (Figure 2-8B). Interactions with F193 and V114 at F11 were again more common  
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Figure 2-8. Biogenic and non-biogenic ligands have distinct interaction fingerprints with the 
β2AR. (S,R’)-Fenoterol, (R,R’)-fenoterol, ritodrine, terbutaline, and clenbuterol were docked to 
inactive structures (3NYA, 3NY8, 5D5B) and active structures (4LDE, 4LDL, 4LDO) of the 
β2AR. From the top 30 poses, ligand interactions were matched with structural features F1-F11 
and added for each crystal structure. A. The non-G protein-biased (S,R’)-fenoterol was compared 
to the Gαs-biased (R,R’)-fenoterol. B. The biogenic (S,R’)-fenoterol was compared to the non-
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biogenic clenbuterol. C. The biogenic (S,R’)-fenoterol was compared to the partially biogenic 
ritodrine. D. The partially biogenic terbutaline was compared to the non-biogenic clenbuterol. 
Interactions are displayed as Residue-interaction type (D- hydrogen bond donor, DD- strong 
hydrogen bond donor, I- ionic, II- strong ionic, A- hydrogen bond acceptor, AA- strong hydrogen 
bond acceptor, C- contact, R- arene, RR- strong arene). Residues followed by a b (e.g., G90b) 
indicate an interaction with the peptide backbone of the corresponding residue. 
  
79 
with (S,R’)-fenoterol, although interactions with V114 had a greater tendency to be aromatic than 
seen with formoterol. (S,R’)-fenoterol also had more hydrogen bonding interactions at F1, 
particularly with S207, S203, and the backbone of C191. 
To confirm the importance of interactions at F11, we compared (S,R’)-fenoterol to 
ritodrine (Figure 2-8C). Ritodrine can induce MB at low but not high concentrations and is 
structurally similar to fenoterol with identical features F3, F4, F5, F7, F8, F10, and F11 (that is, 
differing only at F1, F2, F6, and F9).566 At F11, (S,R’)-fenoterol interacted more frequently with 
F193 than ritodrine. Because these ligands share a common feature F11 but differ in biogenic 
status, the interaction of F193 with F11 is important for β2AR-mediated MB. 
To confirm the importance of interactions at F1, we compared terbutaline to clenbuterol 
(Figure 2-8D). Like ritodrine, terbutaline induces MB at low but not high concentrations.566 
Terbutaline is also structurally similar to clenbuterol, sharing identical features F3-F11 (that is, 
differing only at F1 and F2). At feature F1, terbutaline interacted more frequently with S203, 
S207, and N293. When considered with the interaction profiles of formoterol and (S,R’)-
fenoterol, these data suggest that interactions with S203 and S207 at feature F1 are important for 
β2AR-mediated MB. Interestingly, terbutaline also interacted more frequently with F193 at F8, 
F19, F10, and F11 than clenbuterol, suggesting that the 2,5-hydroxyl substituted ring of 
terbutaline and fenoterol facilitates interactions with F193 at features F8-F11. 
Discussion 
MB plays a vital role in regulating cellular metabolism, differentiation, and repair, and its 
pharmacologic induction has great therapeutic potential in a variety of disease states.235,588 Here, 
we show that in RPTC, formoterol, but not clenbuterol, activates the Gβγ-Akt-eNOS-sGC 
signaling pathway and that this pathway is necessary for formoterol-induced MB (Figure 2-9). 
Importantly, these experiments were performed in metabolically competent primary cells that can 




Figure 2-9. Formoterol, but not clenbuterol, induces MB in a Gβγ-Akt-NOS-sGC-dependent 
manner despite increased cAMP accumulation. Both formoterol and clenbuterol activate Gαs-
dependent signaling to activate adenylate cyclase (AC) and promote cAMP accumulation. 
However, only formoterol activates the Gβγ-PI3K-Akt-eNOS-sGC pathway, and it is this 
pathway that is necessary for β2AR-induced MB in RPTC. 
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in vivo signaling and metabolism compared to immortalized cell lines. Therefore, these data 
suggest a novel role of Gβγ-dependent signaling for GPCR-mediated MB in other non-renal 
tissues. 
The Gβγ heterodimer is released from heterotrimeric G proteins following GPCR 
activation. Gβγ is primarily activated by the Gi/o family of G proteins; however, other G protein 
families, including Gs, release Gβγ.598 Gβγ heterodimers have varied effects on signal 
transduction, including PI3K activation, adenylate cyclase stimulation, adenylate cyclase 
inhibition, MAPK activation, and GRK activation, depending on their constituent Gβ and Gγ 
subunits.599 GPR43 was shown to signal through Gβγ and its activation by acetate induced MB,600 
but the lack of inhibitor studies meant that a causal link between Gβγ and MB was not 
established. By pretreating cells with the Gβγ inhibitor gallein, we identified that Gβγ-dependent 
signaling is a key pathway for GPCR-mediated MB. 
It is important to note that the present study does not determine whether or not Gβγ 
directly activates the PI3K-Akt pathway. In addition to the activation of the Ras-PI3K-Akt 
pathway, Gβγ can also facilitate GRK2 recruitment to the receptor and lead to arrestin-dependent 
signaling. Arrestins are also capable of activating Akt in a PI3K-Src-dependent mechanism.601 
However, given that the arrestin-biased agonist isoetharine is unable to induce MB,566 this 
mechanism is unlikely. 
Prolonged activation of Akt enhances cellular survival but can lead to a decrease in 
mitochondrial function.602-604 In contrast, acute activation of Akt is responsible for the effects of 
multiple inducers of MB, including (-)-epicatechin and erythropoietin.326,605 For such compounds, 
the role of Akt seems to be limited to the phosphorylation of eNOS, leading to NO generation. 
Nitric oxide is a potent inducer of MB in vitro and in vivo through the activation of sGC and 
subsequent cGMP accumulation.606 However, because NO is a free radical, sustained NOS 
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activation can increase oxidative and proteotoxic stress and can inhibit complex I of the electron 
transport chain.607,608 Thus, both the signaling cascade activated by a compound and the duration 
of that signaling contribute to the therapeutic potential of inducers of MB. 
Interestingly, there are conflicting data regarding the role of Gβγ in acute organ injury, 
which is frequently characterized by mitochondrial dysfunction. Inhibition of Gβγ by gallein 
inhibits RPTC proliferation and thereby exacerbates ischemic AKI.609 In contrast, gallein also 
prevents inflammatory cell infiltration,592 leading to enhanced recovery following ischemic 
AKI.610 Although neither study assessed mitochondrial activity, both regeneration following 
injury and inflammatory cell chemotaxis are enhanced by increases in mitochondrial 
activity.230,611 
The β2AR is a prototypical class A GPCR and has been extensively studied for its role in 
cellular signaling and the structural features that enable such signaling. This study is the first to 
examine the receptor-ligand interactions that distinguish mitochondrial biogenic β2AR agonists 
from non-biogenic β2AR agonists. As expected for two agonists of the β2AR, formoterol and 
clenbuterol have a common pharmacophore, and many of the interactions showed little 
preference for formoterol or clenbuterol. Nonetheless, the structural dissimilarities of the two 
compounds led to several distinct receptor-ligand interactions. In particular, interactions with 
V114 and F193 tended to occur more frequently at the methoxyphenyl group on formoterol, 
while C191 and its peptide backbone interacted more frequently with the formamide group of 
formoterol. To enable these interactions to occur, formoterol binds to the β2AR in a conformation 
that places it near the deeper pocket residues of TM3 and TM5 as well as near the shallower 
residues of TM2, ECL2, and ECL4. Our observation of the proximity to ECL2 and ECL4 with 
formoterol is in agreement with NMR studies showing that formoterol weakens the ionic 
interaction between D192 and K305.612 Furthermore, ECL2 flexibility is important to ligand 
activity at the β2AR and for other GPCRs, such as the D2 dopamine receptor.613 
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Modeling interactions of other β2AR agonists with the receptor further supported the role 
of a subset of receptor ligand interactions in stabilizing conformations of the β2AR that lead to 
MB. When compared to the non-biogenic agonist clenbuterol or the partial agonist of MB 
ritodrine, the hydroxyphenyl group (F11) of (S,R’)-fenoterol was more likely to engage in contact 
interactions with F193 and hydrogen bond donor interactions with C191 and its backbone. 
Additionally, its 3,5-hydroxyl groups (F1) were more likely to act as hydrogen bond donors for 
S203 and S207. These results are in agreement with previous docking studies of fenoterol with 
the β2AR.614 Similarly, when compared to clenbuterol, the partial agonist of MB terbutaline had 
more contact interactions between its tert-butyl group (F8-F11) and F193 and hydrogen bond 
donor interactions between its 3,5-hydroxyl groups (F1) and S203, S207, and N293. Previous 
docking studies with terbutaline identified interactions between terbutaline and F193 but not 
between S203, S207, or N293.615 However, those studies generated homology models of the rat 
β2AR from 2rh1, which represents an inactive conformation of the receptor,616 while our study 
employed both active and inactive structures of the β2AR.  
Previous NMR studies have shown that formoterol and clenbuterol engage different 
conformations of the β2AR,617 particularly regarding the conformational shift of TM6. Indeed, 
numerous studies using NMR and mass spectrometry have shown that functionally similar 
agonists can effect distinct active conformations of the receptor.618-620 Additionally, the 
conformational flexibility of the β2AR allows for multiple “active” conformations that may lead 
to differences in effector coupling.  Among its active conformations, formoterol may stabilize a 
set of biogenic β2AR conformations that are thermodynamically unfavorable for clenbuterol. 
In conclusion, this study identified a distinct signaling pathway activated by the 
mitochondrial biogenic β2AR agonist formoterol but not by the non-biogenic β2AR agonist 
clenbuterol in metabolically competent primary cells. This Gβγ-Akt-eNOS-sGC pathway is 
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necessary for the transcriptional and functional changes associated with MB. We also identified 
distinct structural features and ligand interactions that may allow formoterol to activate this 
pathway. Together, these data can facilitate the development of novel β2AR agonists that 
selectively stimulate the Gβγ-Akt-eNOS-sGC pathway to induce MB and recovery from acute 
and chronic degenerative diseases. 
Methods 
Reagents. Anti-GAPDH antibody was purchased from Fitzgerald Antibodies (Acton, MA) and 
was used at a dilution of 1:1,000. Anti-phospho-Akt (Ser473), anti-Akt, and anti-phospho-eNOS 
(Ser1177) antibodies were purchased from Cell Signaling (Danvers, MA) and were all used at a 
dilution of 1:1,000. Anti-eNOS antibody (1:500 dilution), anti-mouse IgG (1:10,000 dilution), 
and anti-rabbit IgG (1:2,000 dilution) antibodies were purchased from Abcam (Cambridge, MA). 
MK2206 and GDC0068 were purchased from SelleckChem (Houston, TX). Gallein, LY294002, 
L-NAME, and ODQ were purchased from Tocris (Ellisville, MO). All other chemicals were 
purchased from Sigma (St. Louis, MO). 
Isolation and culture of proximal tubule cells. Female New Zealand white rabbits (1.5-2.0 kg) 
were purchased from Charles River Laboratories (Wilmington, MA). RPTCs were isolated via the 
iron oxide perfusion method, and RPTCs were cultured under improved conditions as described 
previously621,622. Three days after initial playing, dedifferentiated RPTCs were trypsinized and 
replated on XF-96 polystyrene culture microplates (Seahorse Bioscience, North Billerica, MA) at 
a density of 18,000 cells/well and were maintained at 37oC for 3 days before pharmacological 
manipulation. For other RPTC experiments, isolated renal proximal tubules were plated in 35 mm 
dishes and used at confluence 6 days after initial plating. All experiments were carried out in 
accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals 
of the National Institutes of Health. All procedures were approved by the Institutional Animal 
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Care and Use Committees of the Medical University of South Carolina and the University of 
Arizona and appropriate efforts were made to reduce animal suffering. 
Measurement of oxygen consumption. The oxygen consumption rate (OCR) of RPTCs was 
measured using the Seahorse Bioscience XF-96 Extracellular Flux Analyzer as previously 
described.623 RPTCs in 96-well assay plates were treated with vehicle control (dimethylsulfoxide 
(DMSO), <0.5%) or with experimental compounds. Basal OCR was measured, followed by 
injection of 10 µM carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) to allow for 
the measurement of uncoupled OCR (FCCP-OCR), a marker of MB. 
Protein isolation and immunoblotting. Freshly isolated RPTCs were suspended in protein lysis 
buffer (1% Triton X-100, 150 mM NaCl, and 10 mM Tris-HCl, pH 7.4; 1 mM EDTA; 1 mM 
EGTA; 2 mM sodium orthovanadate; 0.2 mM phenylmethylsulfonyl fluoride; 1 mM HEPES, pH 
7.6) containing protease inhibitors and phosphatase inhibitors (Sigma-Aldrich, St. Louis, MO). 
Following sonication, protein was quantified using a bicinchoninic acid assay, subjected to SDS-
PAGE, transferred onto nitrocellulose membranes, and incubated with primary and secondary 
antibodies. Membranes were detected using chemiluminescence and processed using ImageJ 
(NIH, Bethesda, MD) software. 
Nucleic acid isolation and quantitative polymerase chain reaction. To measure RNA expression, 
RPTC were scraped in TRIzol (Life Technologies, Grand Island, NY), and RNA was isolated 
using a phenol-based centrifugation method. cDNA was reversed transcribed from 5 µg RNA 
using the iScript Advanced cDNA Synthesis Kit (BioRad, Hercules, CA), diluted 1:10, and 5 µL 
added to a real-time SYBR green quantitative polymerase chain reaction master mix (BioRad). 
Changes in gene expression were calculated based on the Δ-Δ threshold cycle method. The 
following primers were used: PGC1α forward (AGGAAATCCGAGCCGAGCTGA), PGC1α 
reverse (GCAAGACGGAGACACATCAAA), NDUFS1 forward 
(AGATGATTTGGGAACAACAG), NDUFS1 reverse (TAGGGCTTAGAGGTTAGAGC), 
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tubulin forward (CTCTCTGTCGATTACGGCAAG), and tubulin reverse 
(TGGTGAGGATGGAGTTGTAGG). 
To measure mtDNA copy number, RPTC were scraped in phosphate buffered saline, and 
DNA was extracted using the DNeasy Blood and Tissue kit (QIAGEN, Valencia, CA). PCR 
products were amplified from 50 ng of cellular DNA using a real-time SYBR green quantitative 
polymerase chain reaction master mix (BioRad). For estimation of mtDNA, the NADH 
dehydrogenase subunit 6 (ND6) gene was used and normalized to tubulin. The following primers 
were used: ND6 forward (ACTGCGATGGCAACTGAGGAGTAT), ND6 reverse 
(ACCATAACTATACAACGCCGCCAC), tubulin forward (CTCTCTGTCGATTACGGCAAG), 
and tubulin reverse (TGGTGAGGATGGAGTTGTAGG). 
Measurement of cyclic nucleotides. RPTCs in 35-mm dishes were treated with vehicle control or 
the compound of interest for 1 h. RPTCs were then harvested according to the manufacturer’s 
protocol (Cayman Chemical, Ann Arbor, MI). Levels of cAMP and cGMP were measured using 
a commercially available enzyme-linked immunosorbent assay kit. Values were normalized to 
protein as quantified by a bicinchoninic acid assay followed by normalization to vehicle control 
for each biological replicate. 
Molecular modeling. Modeling, simulations, and visualizations were performed using MOE 
(Molecular Operating Environment) version 2015.1001 (Chemical Computing Group). The 
structural files used as input for analysis and docking simulations were PDB codes 3NYA, 3NY8, 
4LDE, 4LDL, 4LDO, and 5D5B. Before analysis and simulations, all atoms and molecules other 
than the receptor and the ligand were removed. The receptor and all ligands were protonated at 
pH 7.4 in MOE. Initial placement calculated 30 poses per molecule using triangle matching 
placement with London dG scoring. All 30 poses were then refined using induced fit with London 
dG scoring. Ligand interactions were assessed using the protein-ligand interaction fingerprint 
(PLIF) function in MOE. To score interaction frequencies, interactions with individual atoms 
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were tabulated. Interactions with the active ligand formoterol were assigned a value of 1, while 
interactions with the inactive ligand clenbuterol were assigned a value of -1, and interactions for 
all poses across all crystal structures were added to generate overall ligand interaction frequencies 
at structural features. 
Statistical analysis. Data are expressed as means + S.E.M. (N > 3) for all experiments. Each N 
represents a biological replicate. Multiple comparisons of normally distributed data were 
analyzed by one-way analysis of variance, as appropriate. Single comparisons were analyzed with 
the Wilcoxon signed rank test where appropriate. The criterion for statistical differences was 













CHAPTER 3  
PROXIMAL TUBULE CELL DELETION OF THE β2 ADRENERGIC RECEPTOR 
PREVENTS FORMOTEROL-INDUCED RECOVERY OF MITOCHONDRIAL AND RENAL 






AKI is a rapid loss of renal function that occurs in over 20% of hospitalized patients and 
has a mortality rate of 25%.2,3 AKI has numerous causes, including hypotension, nephrotoxic 
drug administration, and renal ischemia-reperfusion injury (IRI).5 Unfortunately, treatment of 
AKI remains limited to supportive care and renal replacement therapy.  
The difficulty in treating AKI is the numerous cell types involved, including immune 
cells,139 endothelial cells,624 and the renal epithelium.113 RPTC are a highly oxidative and 
regenerative cell type that plays a central role in the pathogenesis of AKI.176,177 RPTC exhibit 
mitochondrial fragmentation and dysfunction with persistent suppression of MB after 
AKI.203,205,207 Transgenic mouse models have shown that decreased MB worsens AKI, while 
increased MB accelerates recovery.625 
Drugs that increase MB accelerate recovery from AKI with concomitant rescue of 
mitochondrial protein expression and function.567 One such drug is the FDA-approved β2AR 
agonist formoterol.567  We reported that formoterol treatment restored renal function with 
concomitant increases in mitochondrial protein expression and function after AKI in mice.231 
Recently, we elucidated the mechanism of formoterol-induced MB in RPTC.626 Formoterol 
binding to the β2AR results in the release of Gβγ heterodimer, the activation of Akt, the 
phosphorylation of eNOS, and increased soluble guanylyl cyclase activity and cGMP.  This 
pathway increased PGC-1α, the master regulator of MB,232 with concomitant induction of MB. 
Because the β2AR is ubiquitously expressed (e.g. T cells, macrophages, neutrophils, 
endothelial cells and RPTC), it is not clear which cell(s) are responsible for formoterol induced 
MB and recovery of renal function following IR-induced AKI. The goal of this study was to 
determine the specific role of RPTC β2AR in AKI and formoterol-induced recovery of 
mitochondrial and renal function using a mouse with proximal tubule specific deletion of the 
β2AR.627 
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Results and Discussion 
RPTC-specific deletion of the β2AR in mice was achieved by breeding γGT-Cre mice 
with ADRB2Flox/Flox (WT) mice to create a γGT-Cre:ADRB2Flox/Flox mouse (KO) (Figure 3-1A). 
To assess expression of the β2AR in RPTC in these mice, renal cortical ADRB2 DNA and mRNA 
were measured using qPCR. Consistent with loss of β2AR in RPTC, KO mice had an 80% 
reduction in renal cortical ADRB2 DNA and mRNA expression and increased γGT-Cre DNA 




Figure 3-1. γGT-Cre:ADRB2Flox/Flox mice have proximal tubule specific deletion of the β2 
adrenergic receptor. A. DNA electrophoresis of: an ADRB2+/+ mouse homozygous for ADRB2+ 
(lane 1) and not expressing gGT-Cre (lane 2); a mouse γGT-Cre:ADRB2+/+ homozygous for 
ADRB2+ (lane 3) and expressing gGT-Cre (lane 4); and a γGT-Cre:ADRB2Flox/Flox mouse 
homozygous for ADRB2Flox (lane 5) and expressing gGT-Cre (lane 6).  B. RT-PCR of ADRB2 
mRNA in ADRB2Flox/Flox and γGT-Cre:ADRB2Flox/Flox mice. C, D. PCR of ADRB2 (C) and γGT-






The role of RPTC β2AR on recovery from AKI was determined in KO and WT mice 
subjected to renal IRI followed by treatment with vehicle or formoterol (0.3 mg/kg, i.p) after 24 h 
and then daily for 144 h. WT and KO mice had similar increases in SCr at 24 h, indicating no 
difference in initial injury (Figure 3-2A). As previously described,231 WT mice treated with 
formoterol exhibited recovery from AKI at 144 h as measured by decreases in SCr and renal 
cortical KIM-1 protein (Figure 3-2B, E). In contrast, KO mice treated with formoterol did not 
exhibit decreases in SCr and renal cortical KIM-1 at 144 h. These findings were confirmed by 
histopathology in that formoterol-treated WT mice had less necrosis than vehicle-treated animals, 
while formoterol failed to decrease necrosis in KO mice at 144 h (Figure 3-2C, D). Together, 
these findings provide evidence that following AKI, formoterol exerts its effects on renal 




Figure 3-2. Proximal tubule deletion of the β2 adrenergic receptor blocks the effects of 
formoterol on renal function following AKI. ADRB2Flox/Flox and γGT-Cre:ADRB2Flox/Flox mice 
were subjected to sham or renal IRI surgery. Mice were treated with 0.3% DMSO (Vehicle) or 
0.3 mg/kg formoterol (Formoterol) once daily beginning at 24 h and were euthanized at 144 h. A, 
B.) Serum creatinine at 24 h (A) and 144 h (B) following IR. C.) PAS stained kidney sections. 
D,E.) Semi-quantitative scoring of tubular necrosis (D). E.) Representative blot of renal cortical 
KIM-1 at 144 h following IRI. FFS-ADRB2Flox/Flox sham, FFV-ADRB2Flox/Flox IR+0.3% DMSO, 
FFF-ADRB2Flox/Flox IR+0.3 mg/kg formoterol, CFS-γGT-Cre:ADRB2Flox/Flox Sham, CFV- γGT-
Cre:ADRB2Flox/Flox IR+0.3% DMSO, CFF- γGT-Cre:ADRB2Flox/Flox IR+Formoterol. Mean+SEM. 
N=4-9. Different letters denote p<0.05, Two-Way ANOVA with Fisher’s LSD test. 
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 RPTC have high mitochondrial content to maintain proper solute transport across the 
tubular lumen.112,175,176 Following AKI, MB is persistently suppressed and recovery of 
mitochondrial content is associated with recovery of renal function and improved outcomes.205 
The effects of RPTC β2AR on mitochondrial content were assessed by measuring mtDNA and 
mitochondrial proteins using qPCR and immunoblot analysis, respectively. Formoterol restored 
mtDNA copy number in WT but not KO mice after IRI (Figure 3-3A). Similarly, KO mice 
subjected to IRI and treated with formoterol demonstrated no recovery of nuclear-encoded 
NDUFS1 and the mitochondrial-encoded COX1, electron transport chain (ETC) proteins and 
markers of MB (Figure 3-3B). Thus, activation of RPTC β2AR by formoterol rescues markers of 
MB following AKI.  Interestingly, KO shams had elevated expression of NDUFS1, which 




Figure 3-3. Proximal tubule cell β2 adrenergic receptor mediates formoterol-induced rescue of 
mitochondrial homeostasis following IRI-AKI. A.) Mitochondrial DNA copy number. B.) 
Representative blots and quantification of nuclear-encoded (NDUFS1) and mitochondrial-
encoded (COX1) proteins in renal cortex 144 h after IRI. C.) Representative blots and 
quantification of mitochondrial dynamic proteins Mfn2 and Drp1 in renal cortex 144 h after IRI. 
FFS-ADRB2Flox/Flox sham, FFV-ADRB2Flox/Flox IR+0.3% DMSO, FFF-ADRB2Flox/Flox IR+0.3 
mg/kg formoterol, CFS-γGT-Cre:ADRB2Flox/Flox sham, CFV- γGT-Cre:ADRB2Flox/Flox IR+0.3% 
DMSO, CFF- γGT-Cre:ADRB2Flox/Flox IR+0.3 mg/kg Formoterol. Mean+SEM. N=4-9. Different 
letters denote p<0.05, Two-Way ANOVA with Fisher’s LSD test. 
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To further understand mitochondrial changes under these experimental conditions in the 
absence and presence of formoterol, electron micrographs were obtained and mitochondrial 
number and morphology were quantified using ImageJ and the Trainable Weka Segmentation 
plugin. In WT mice, renal cortical mitochondrial number and total mitochondria area decreased 
after IRI and formoterol restored these parameters, indicating that formoterol induced MB (Figure 
3-4A-C). Sham-operated KO mice had fewer mitochondria, providing evidence that RPTC β2AR 
regulates mitochondrial homeostasis under physiological conditions. 
In addition to the restoration of ETC proteins, formoterol restored mitochondrial fission 
and fusion proteins Drp1 and Mfn2, respectively, in WT but not KO mice (Figure 3-3C). Because 
Drp1 and Mfn2 are regulated by the PGC-1α,246,628,629 and expression of both proteins is restored 
following formoterol-treatment in WT mice, the recovery of Mfn2 and Drp1 is linked to 
formoterol-induced activation of PGC-1α. Drp1 is thought to be detrimental following injury by 
enhancing mitochondrial fragmentation, reactive oxygen species production, and apoptosis.225 
Following AKI, mitochondrial fragmentation is increased in RPTC in a Drp1-dependent manner 
203, and decreased Mfn2 expression potentiates this fragmentation.227,630  As such, formoterol 
activation of β2AR and restoration of Drp1 and Mfn2 expression may improve mitochondrial 





Figure 3-4. The role of proximal tubule-cell β2 adrenergic receptor on mitochondrial content and 
morphology in renal cortex. A.) Representative electron micrographs of ADRB2Flox/Flox and γGT-
Cre:ADRB2Flox/Flox subjected to sham or IRI surgery followed by treatment with 0.3% DMSO or 
0.3 mg/kg formoterol daily for 144 h. B.) Quantification of mitochondria per field. C.) 
Quantification of total mitochondrial area per field. All images were acquired at x8,200 
magnification with at least 5 fields per animal. N=3-8. Mean+SEM. Different letters indicate 
p<0.05, Two-Way ANOVA with Fisher’s LSD test. 
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Proper balance of MB, fission, and fusion is important for recovery from AKI. Deletion 
of PGC-1α, a key transcriptional regulator of MB, worsens RPTC injury while its overexpression 
promotes MB to accelerate recovery.205,625 Pharmacologic induction of MB accelerates recovery 
of mitochondrial and renal function following AKI.231,631,632 Formoterol-treated mice lacking the 
β2AR in RPTC failed to recover mtDNA copy number, mitochondrial protein expression, and 
mitochondrial number and area following AKI. In addition, sham-operated KO mice had fewer 
total mitochondria without a decrease in mtDNA copy number and elevated NDUFS1 protein 
expression. These data provide evidence that the β2AR plays a role in RPTC mitochondrial 
homeostasis in healthy mice. While previous studies have shown that formoterol increases 
mRNA, protein, and functional markers of mitochondria in the kidney,231,567 this study shows for 
the first time that formoterol induces bona fide MB in RPTC. In summary, these data underscore 
the importance of RPTC mitochondria as a therapeutic target, that β2AR regulates renal 
mitochondrial homeostasis, and that GPCR ligands such as formoterol can induce MB to 
accelerate recovery from renal function.  
Methods: 
Animal Use. ADRB2Flox/Flox mice were mated with γGT-Cre mice to obtain γGT-
Cre:ADRB2Flox/Flox mice. Eight- to ten-week-old mice  were subjected to bilateral renal ischemia-
reperfusion injury as previously described.207 Dosing was initiated 24 h after reperfusion, and 
mice were given a daily injection of 0.3 mg/kg formoterol fumarate dihydrate (Sigma-Aldrich 
F9552) or vehicle (0.3% DMSO in normal saline) via intraperitoneal injection.  Blood was 
collected by retro-orbital bleeding puncture and serum creatinine (SCr) was determined using the 
Creatinine Enzymatic Reagent Assay kit (Diazyme) according to manufacturer’s protocol. All 
experiments were carried out in accordance with the recommendations in the Guide for the Care 
and Use of Laboratory Animals of the National Institutes of Health. All procedures were 
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approved by the University of Arizona Institutional Animal Care and Use Committee and 
appropriate efforts were made to reduce animal suffering. 
Nucleic acid isolation and quantitative polymerase chain reaction. RNA was extracted from 
frozen renal cortex in TRIzol isolated using a phenol-based centrifugation method (Life 
Technologies, Grand Island, NY). cDNA was reversed transcribed using the iScript Advanced 
cDNA Synthesis Kit (BioRad, Hercules, CA) and was added to a real-time SYBR green 
quantitative polymerase chain reaction master mix (BioRad). Changes in gene expression were 
calculated based on the Δ-Δ threshold cycle method. Primers are reported in Table 3-1. 
Mouse tail tips were lysed using DirectPCR Lysis reagent (Viagen). Genomic DNA was 
amplified using Promega 2X PCR Master Mix in accordance with manufacturer’s protocols. 
Amplified DNA was separated on a 2.5% agarose gel and visualized by ethidium bromide 
fluorescence. 
To measure mtDNA copy number, DNA was extracted from frozen renal cortex using the 
DNeasy Blood and Tissue kit (QIAGEN, Valencia, CA). PCR products were amplified from 5 ng 
of cellular DNA using a real-time SYBR green quantitative polymerase chain reaction master mix 
(BioRad). For estimation of mtDNA, the NADH dehydrogenase subunit 6 (ND6) gene was used 
and normalized to β-actin. 
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Table 3-1. Primer sequences. 
Gene Forward Reverse 
ADRB2Flox CCA AAG TTG TTG CAC GTC 
AC 
GCA CAC GCC AAG GAG ATT AT 
γGT-Cre GCT CTT GGG AGA AGT CAT 
GC 
CAT GTT TAG CTG GCC CAA AT 
ADRB2 GTA CCG TGC CAC CCA GA CCC GGG AAT AGA CAA AGA CCA 
TC 
ND6 TCC AAA CAC AAC CAA CAT 
CC 
TTG GCA TTA AAG CCT TCA CC 
β-Actin GGG ATG TTT GCT CCA ACC 
AA 




Protein isolation and immunoblotting. Frozen renal cortex was suspended in protein lysis buffer 
(1% Triton X-100, 150 mM NaCl, and 10 mM Tris-HCl, pH 7.4; 1 mM EDTA; 1 mM EGTA; 2 
mM sodium orthovanadate; 0.2 mM phenylmethylsulfonyl fluoride; 1 mM HEPES, pH 7.6) 
containing protease inhibitors and phosphatase inhibitors (Sigma-Aldrich, St. Louis, MO). 
Following sonication, protein was quantified using a bicinchoninic acid assay, subjected to SDS-
PAGE, transferred onto nitrocellulose membranes, and incubated with primary and secondary 
antibodies. Membranes were detected using chemiluminescence and processed using ImageJ 
(NIH, Bethesda, MD) software. Antibodies are reported in Table 3-2. 
Electron Microscopy. Renal cortex was fixed and sectioned for transmission electron microscopy. 
Images were viewed by FEI Tecnai Spirit microscope operated at 100 kV and captured using an 
AMT 4 Mpixel camera. Mitochondrial count and morphology were analyzed using the Trainable 
Weka Segmentation plugin in ImageJ. 
Histopathology. Kidney sections approximately 5–6 microns from animals at 144 hours after I/R 
or sham surgery were stained with hematoxylin and eosin and PAS, and the degree of 
morphologic changes was determined by light microscopy in a blinded fashion. Loss of brush 
border and necrosis were chosen as indicators of morphological damage to the kidney. These 
measures were evaluated on a scale from 0 to 4, which ranged from not present (0), mild (1), 
moderate (2), severe (3), and very severe (4). 
Statistical analysis. Data are expressed as means + S.E.M. (N > 3) for all experiments. Each N 
represents a different animal. Multiple comparisons of normally distributed data were analyzed 
by two-way analysis of variance. Single comparisons were analyzed with a T-test where 
appropriate. The criterion for statistical differences was p<0.05 for all comparisons. 
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Table 3-2. Antibodies 
Protein Manufacturer Cat. No. Lot No. Dilution 
Actin Santa Cruz sc-47778 J2816 1:1,000 
Mfn2 Santa Cruz sc-50331 F1614 1:1,000 
Drp1 Santa Cruz sc-32898 F1715 1:1,000 
NDUFS1 Abcam ab96428 GR70572-10 1:1,000 
COX1 Abcam ab14765 GR291384-5 1:1,000 
KIM-1 R&D Systems AF1817 KCA0317041 1:1,000 
Donkey Anti-Goat 
IgG 
Abcam ab97110 GR302038-10 1:5,000 
Goat Anti-Rabbit IgG Abcam ab6721 GR3204153-1 1:2,000 
















CHAPTER 4  
CONCLUSIONS AND FUTURE DIRECTIONS  
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Summary of Relevant Findings 
AKI occurs commonly in hospitalized patients and carries a high morbidity and mortality 
with no treatments beyond renal replacement therapy. AKI is characterized by mitochondrial 
dysfunction, particularly in the RPTC. The induction of MB is a therapeutic target for AKI. Our 
group has shown that formoterol, a β2AR agonist, can induce MB in vitro and in vivo, and 
stimulate recovery of mitochondrial and renal function following AKI in mice.  
Our in vitro study using rabbit RPTC elucidated the signaling pathway by which 
formoterol induces MB. The results showed that formoterol induces MB through a Gβγ-Akt-
eNOS-cGMP-dependent pathway, while clenbuterol fails to activate this pathway. This study was 
the first to associate Gβγ- and cGMP-dependent signaling with β2AR-induced MB. 
Understanding differences in ligand bias enable more targeted application of 
pharmacotherapy to various disease states. Having identified differences in signaling between 
formoterol and clenbuterol, we hypothesized that these ligands interacted with the β2AR at 
different residues. To understand the structural basis of these differences in signaling, formoterol 
and clenbuterol were docked to the orthosteric binding site of both inactive (3NYA, 3NY8, 
5D5B) and active (4DLE, 4LDL, 4LDO) crystal structures of the β2AR. For each pose, receptor-
ligand interactions were tabulated at each structural feature. Each interaction was assigned a value 
of +1 for formoterol and -1 for clenbuterol, and interactions were summed for all six crystal 
structures. The methoxyphenyl group of formoterol showed a greater likelihood of aromatic 
interactions with W109 and V114 and contact interactions with F193. Interestingly, the 
formamide and hydroxyl groups of formoterol exhibited a greater interaction frequency with the 
backbone of C191, but the amino group of clenbuterol was more likely to engage in strong 
interactions at that site. Similarly, the secondary amino group of both formoterol and clenbuterol 
interacted with D113, but formoterol was more likely to do so with strong hydrogen bond or ionic 
interactions. Overall, the longer and larger functional groups of formoterol allowed it to stretch 
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across the binding pocket of the β2AR receptor to simultaneously interact with TM3, TM5, and 
ECL2 in a manner distinct from clenbuterol and may drive the differences in signaling between 
formoterol and clenbuterol. These interaction profiles provide key structural data for the 
development of β2AR agonists that selectively activate specific signaling programs. 
AKI is the transient loss of renal function following an insult, such as nephrotoxicant 
exposure, sepsis, or ischemia. Numerous cell types play a role in the pathogenesis of AKI, 
including immune, endothelial, and RPTC. Our laboratory has demonstrated that the β2AR 
agonist formoterol accelerates the recovery of renal function in mice following ischemia-
reperfusion injury (IRI) with associated rescue of mitochondrial proteins. However, the cell type 
or types responsible for this recovery remain unknown. 
To assess the role of RPTC in formoterol-induced recovery of renal function, we 
generated a proximal tubule-specific knockout of the β2AR (γGT-Cre:ADRB2Flox/Flox). These mice 
were subjected to renal IRI, followed by once daily dosing with formoterol beginning at 24 h and 
euthanasia at 144 h. Compared to wild-type controls (ADRB2Flox/Flox), the γGT-Cre:ADRB2Flox/Flox 
mice had lower renal cortical mRNA expression of the β2AR. Following IRI, vehicle-treated 
ADRB2Flox/Flox and γGT-Cre:ADRB2Flox/Flox mice exhibited a modest but incomplete recovery of 
renal function as measured by serum creatinine. Treatment with formoterol restored renal 
function in ADRB2Flox/Flox but not γGT-Cre:ADRB2Flox/Flox  mice. Similarly, formoterol decreased 
renal injury as measured by KIM-1 and tubular necrosis in ADRB2Flox/Flox but not γGT-
Cre:ADRB2Flox/Flox  mice. Interestingly, treatment with formoterol restored brush border in both 
genotypes, albeit to a lesser extent in γGT-Cre:ADRB2Flox/Flox mice. Together, these data 
demonstrate that formoterol acts through RPTC β2AR to exert its effects on renal function in 
AKI. 
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Many acute organ injuries and chronic degenerative diseases, including AKI, are 
associated with persistent disruptions in mitochondrial homeostasis. The induction of MB is 
therefore a promising therapeutic target for such diseases, particularly AKI. Our laboratory has 
demonstrated that treatment with the β2AR agonist formoterol accelerates the recovery of renal 
function following AKI with associated rescue of mitochondrial protein expression. However, 
true MB (i.e., the formation of new mitochondria) has not been demonstrated. Mice lacking the 
β2AR in proximal tubule cells (γGT-Cre:ADRB2Flox/Flox) and wild-type controls (ADRB2Flox/Flox) 
were subjected to renal IRI, followed by once daily treatment with formoterol beginning 24 h and 
euthanasia at 144 h. At 144 h, ADRB2Flox/Flox mice treated with formoterol exhibited recovery of 
mitochondrial DNA copy number (mtDNA) and the electron transport chain proteins NDUFS1 
and COX1. However, γGT-Cre:ADRB2Flox/Flox mice treated with formoterol did not demonstrate 
recovery of mtDNA, NDUFS1, or COX1. Similarly, ADRB2Flox/Flox mice treated with formoterol 
demonstrated recovery of the mitochondrial fission and fusion proteins Drp1 and Mfn2, while 
expression of these markers was unaffected by formoterol treatment in γGT-Cre:ADRB2Flox/Flox 
mice. To determine whether the recovery of mtDNA and mitochondrial protein expression was 
due to increased MB, electron microscopy was used to quantify mitochondrial number and 
morphology. In ADRB2Flox/Flox mice but not γGT-Cre:ADRB2Flox/Flox mice, formoterol treatment 
increased both mitochondrial number and the total mitochondrial area following IR relative to 
vehicle-treated mice. In both genotypes, mice subjected to IRI regardless of treatment had 
increased mitochondrial roundness, consistent with injury. There was no difference in 
mitochondrial form factor among the groups, despite the changes in Drp1 and Mfn2 protein 
expression. Together, these data show for the first time that formoterol acts on RPTC β2AR to 
induce MB to accelerate recovery of renal function following AKI.  
These studies demonstrated that formoterol activates a Gβγ-Akt-eNOS-cGMP signaling 
pathway to induce MB in RPTC. This pathway was not activated by all β2AR agonists, and 
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activation of this pathway correlated with specific receptor-ligand interaction profiles. We 
demonstrated that formoterol acts on RPTC β2AR to accelerate the recovery of renal function and 
mitochondrial protein expression. Finally, using electron microscopy, we demonstrated that 
formoterol increases mitochondrial number and density in RPTC. These studies demonstrate that 
specific GPCR-ligand interactions can drive distinct signaling pathways to affect mitochondrial 
homeostasis and organ function. 
Future Directions 
We have identified that formoterol, but not clenbuterol, activates a Gβγ-Akt-eNOS-
cGMP pathway to induce MB. Furthermore, we found distinct receptor-ligand interaction profiles 
for β2AR agonists that induce and do not induce MB. These data are suggestive of biased 
agonism through the β2AR. The key determinant of ligand bias is reversal of efficacy.633 In 
primary RPTC, both formoterol and clenbuterol increased cAMP accumulation, but clenbuterol 
was less efficacious than formoterol (Figure 4-1A). Treatment with formoterol, but not 
clenbuterol, also activated Akt in a concentration-dependent manner (Figure 4-1B), and neither 
agonist affected ERK1/2 phosphorylation (Figure 4-1C). These data fail to prove bias between the 
two ligands, as the increased efficacy of formoterol may reach a threshold to activate Akt 
phosphorylation. Furthermore, previous studies in other cell lines identified clenbuterol as a 
partial agonist for cAMP. Based on these data, further work is required to elucidate the potential 
impact of biased agonism on β2AR-mediated MB.  
While primary RPTC are a useful tool for the identification of inducers of MB and for 
confirmation of signaling pathways,634 their recalcitrance to genetic manipulation (and therefore 
reliance on pharmacologic inhibitors) makes them a lesser model for elucidation of ligand bias. 
As such, cell lines must be identified that: recapitulate the effects of our panel of β2AR agonists 
on MB; and demonstrate similar signaling as observed in RPTC following formoterol stimulation. 
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Once a model is developed, the efficacy of β2AR agonists for various signaling pathways 
(e.g., cAMP/PKA, NO/cGMP, Ca+2-dependent signaling) can be identified. Based on efficacy 
profiles, signaling pathways that are activated by inducers of MB can be identified. Furthermore, 
agonists can be clustered based on their efficacy profiles, and these clusters can be compared to 
pharmacophore models and docking experiments to identify structural determinants of these 
signaling pathways. Using immortalized cell lines also allows for elucidation of the effects of 
formoterol and other β2AR agonists on G protein, arrestin, and kinase recruitment to the β2AR.  
Pre-treatment with the GRK2 inhibitor Cmpd101 prevented formoterol-induced increases 
in FCCP-OCR without affecting Akt phosphorylation (Figure 4-2), suggesting that formoterol 
activates GRK2 in a pathway distinct or downstream from Akt. Understanding whether this is due 
to a direct interaction between GRK2 and the receptor or through some other pathway would 





Figure 4-1. The effects of formoterol on cAMP accumulation and Akt and ERK1/2 
phosphorylation. RPTC were treated with formoterol or clenbuterol for 30 min. Cyclic 
nucleotides and protein were extracted. cAMP accumulation was measured by ELISA (A). 
Immunoblot analysis was used to assess the phosphorylation of Akt (B) and ERK1/2 (C).  N=3-6. 




Figure 4-2. The effects of GRK2 inhibition on formoterol-induced MB and Akt phosphorylation. 
A. RPTC were pre-treated with 300 nM Cmpd101 (a GRK2/3 inhibitor) for 30 min, followed by 
treatment with formoterol for 24 h. FCCP-OCR was measured using the Seahorse XF96 analyzer. 
B. RPTC were pre-treated with 300 nM Cmpd101 for 30 m, followed by treatment with 
formoterol for 30 min. Akt phosphorylation was assessed by immunoblot. Mean + SEM, N=4-6. 




Formoterol accelerates the recovery of renal function in mice subjected to IR-induced 
AKI. However, there are numerous causes of AKI, and no single mouse model fully recapitulates 
human disease. The disconnect between mouse models and human disease is one of the obstacles 
to the development of effective therapeutics for AKI. As such, the effects of formoterol in other 
models of AKI should be explored. Activation of the β2AR by terbutaline or overexpression is 
renoprotective in mouse models of septic AKI,578-580,635-637 however,  β2AR activation reduces 
creatinine clearance in healthy rats.584 Because formoterol activates Gβγ-dependent signaling 
distinct from other β2AR agonists, the detrimental effects of β2AR signaling observed in the rat 
study may be ameliorated by treatment with formoterol. Additionally, preliminary data in 
proximal tubule cell lines demonstrated that administering formoterol after LPS decreases TNF-α 
mRNA expression at 24 h (Figure 4-3). These data indicate that formoterol may have utility in 




























































































































Figure 4-3. Formoterol decreases TNFα expression following LPS administration in TKPTS 
cells. The proximal tubule TKPTS cell line was treated with LPS (10 µg/mL) for 1 h, followed by 
treatment with 10, 30, or 100 nM formoterol. After 24 h, mRNA was extracted, and TNFα 
expression was measured by RT-qPCR. Mean+SEM, N=5-6. *-p<0.05 vs. Vehicle, #-p<0.05 vs 
LPS 10 µg/mL, One-Way ANOVA. 
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Formoterol is used clinically for the treatment of asthma and COPD, but its use is limited 
by a black-box warning for severe asthma exacerbations. Because airway smooth muscle 
expresses high levels of β2AR, current inhaled formulations are designed to minimize systemic 
distribution of formoterol. However, for AKI, an intravenous or oral formulation would be 
required to achieve sufficient drug concentrations in RPTC. Additionally, since its patent has 
expired, formoterol is not an attractive lead compound for drug companies. Two studies would 
help overcome this barrier to clinical translation. One is employing electronic health record 
databases to identify potential correlations between formoterol use and renal dysfunction. Based 
on our preclinical results, we expect that formoterol use is negatively correlated with the 
development of AKI. However, identifying proper patient controls and obtaining a sufficient 
patient population to achieve statistical power may prove challenging.  
Another study to increase the likelihood of successful application of formoterol as 
treatment for AKI is the development of a targeted formulation of formoterol. Recent work has 
identified nanoparticle formulations that selectively target RPTC;638 however, new formulations 
may be necessary to target plasma membrane receptors, as opposed to intracellular targets. A new 
formulation could be patented by drug companies, facilitating the funding of potentially costly 
clinical trials.  
While most patients recover from their initial bout of AKI, they are sensitized to future 
renal and cardiovascular dysfunction, and some patients progress from AKI into CKD. 
Formoterol accelerates the recovery of renal function in the acute recovery phase of AKI. The 
effects of formoterol on the AKI-CKD transition, cardiorenal syndrome, and CKD itself are not 
known. Identifying the therapeutic effects of formoterol in these disease processes would allow 
for more effective identification of patients who would benefit from formoterol administration. 
We generated a mouse with a RPTC-specific deletion of the β2AR and observed that 
RPTC β2AR is necessary for the effects of formoterol on renal function and MB following AKI. 
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Healthy mice lacking RPTC β2AR had normal renal function as measured by SCr; however, we 
observed an increase in NDUFS1 protein expression and increased mitochondrial length. 
Additionally, these mice had fewer mitochondria and a lower mitochondrial density. Given the 
oxidative state of RPTC, it is possible that mice lacking RPTC β2AR have a subclinical disruption 
in mitochondrial homeostasis that disrupts solute transport and sensitizes the kidney to injury. 
The β2AR has been implicated in renal sodium transport and Na+/K+-ATPase expression.639,640 
Urinalysis could be performed on ADRB2Flox/Flox and γGT-Cre:ADRB2Flox/Flox mice to identify 
changes in urinary electrolyte concentrations.  
Additional experiments could be performed on male and female mice of varying ages to 
identify any sex differences or age-dependent differences in renal function caused by lack of the 
β2AR. These experiments would provide an important link between mitochondrial homeostasis 
and basic renal physiology, and these data will inform potential effects of β2AR polymorphisms 
on renal function. 
Endothelial and immune cells play important roles in both the injury and recovery phases 
of AKI.139,624 Because the β2AR is ubiquitously expressed, it is reasonable to infer that formoterol 
exerts an effect on endothelial and immune cell function in AKI and in other diseases. 
Experiments could identify levels of different circulating cytokines at different times after AKI 
and how formoterol affects these cytokines. Because cytokines are secreted by and affect the 
infiltration of different immune cell types, these data will allow for a more focused examination 
of infiltrating immune cells following AKI. 
Administration of formoterol following AKI increases the protein expression of electron 
transport chain proteins as well as proteins associated with mitochondrial fission and fusion. 
However, we found that formoterol did not affect the mRNA expression of PGC-1α, COX1, 
NDUFS1, or ND1 following IR (Figure 4-4). Because tissue was taken after multiple doses of 
formoterol, these findings may be due to a negative feedback pathway following formoterol-
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induced MB that prevent excessive mitochondrial content. Similarly, these findings could be due 
to desensitization of the β2AR following stimulation by formoterol.  
Another potential explanation for these findings is the effect of formoterol on mitophagy, 
or the clearance of damaged mitochondria. Controlled mitophagy is generally renoprotective,212 
but excessive or uncontrolled mitophagy leads to a lethal energy imbalance and subsequent cell 
death.641 The findings of recovered mitochondrial protein but not mRNA expression may suggest 
that formoterol can inhibit mitophagy. Mitophagy is inhibited by mammalian target of rapamycin 
(mTOR), which is a known downstream target of Akt. Because formoterol increases Akt 
phosphorylation, formoterol may play a role in the regulation of mitophagy. 
  To assess the role of mitophagy on the effects of formoterol, protein expression of 
markers of autophagy (e.g., LC3BII, p62, and p-mTOR) could be measured. To confirm that 
changes in these proteins are due to mitophagy rather than general autophagy, the MitoTimer 
mouse could also be used. This mouse has a mitochondrial fluorescent protein that shifts from 
green to red fluorescence following oxidative stress,642 allowing for the visualization of old or 
damaged mitochondria. In this system, red punctate mitochondria are generally considered to be 
targeted for lysosomal degradation. These mice could therefore be used to quickly visualize 
mitochondria in multiple organs to determine the effects of formoterol or other inducers of MB 










































































































































































































































































































































































Figure 4-4. Formoterol does not increase mRNA expression of markers of MB following AKI. 
ADRB2Flox/Flox (Flox/Flox) and γGT-Cre:ADRB2Flox/Flox (CreLox) mice were subjected to renal IR 
followed by treatment with formoterol. mRNA expression of PGC-1α, COX1, NDUFS1, and 
ND1 was measured by RT-qPCR in renal cortex 144 h post-injury. Mean + SEM. N=3-9. 
Different subscripts indicate p<0.05, Two-Way ANOVA followed by Fisher’s LSD test.   
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We identified the Gβγ-Akt-eNOS-cGMP pathway as necessary for formoterol-induced 
MB in vitro. Other work in our lab has identified this pathway as important for 5HT1F receptor-
mediated MB in cultured RPTC.541 The importance of this pathway in vivo remains unclear. 
Preliminary data demonstrated that formoterol increases Akt phosphorylation in mouse renal 
cortex 30 min after administration and that this phosphorylation is blocked by pretreatment with 
gallein (Figure 4-5A, C); furthermore, mice have elevated cGMP levels at 30 and 60 min 
following formoterol administration (Figure 4-5B). At 24 h following formoterol administration, 
renal cortical ATPSβ increased, and this increase was also blocked by pretreatment with gallein 
(Figure 4-5D). To examine the effects of formoterol in AKI, mice were subjected to IRI, followed 
by treatment with formoterol or diluent 24 h after injury. At 30 min after drug administration, Akt 
phosphorylation was elevated regardless of treatment; however, mice treated with formoterol 
exhibited decreased ERK1/2 phosphorylation (Figure 4-6A). In mice treated with formoterol, 
there was decreased renal injury and recovery of renal function and mitochondrial protein 
expression 24 h following drug administration (Figure 4-6B-D). Further work is necessary to 
determine the signaling pathway(s) activated by formoterol in the injured kidney and the role of 




Figure 4-5. Formoterol activates Akt in a Gβγ-dependent manner to induce MB in vivo. A. Male 
C57Bl/6 mice were treated with 0.3 mg/kg formoterol or 0.3 mg/kg clenbuterol for 30 min. Akt 
phosphorylation at S473 was measured in renal cortex. B. Male C57Bl/6 mice were treated for 30 
min or 1 h with 0.3 mg/kg formoterol. Accumulation of cGMP in the renal cortex was measured 
by ELISA. C. Male C57Bl/6 mice were pre-treated with 30 mg/kg gallein for 1 h followed by 
treatment with 0.3 mg/kg formoterol for 30 min. Akt phosphorylation was measured at S473 in 
renal cortex. D. Male C57Bl/6 mice were pre-treated with 30 mg/kg gallein for 1 h followed by 
treatment with 0.3 mg/kg formoterol for 24 h. ATPSβ levels were measured in the renal cortex. 




Figure 4-6.Formoterol modulates ERK1/2 phosphorylation, renal function, and MB early after 
AKI. Male C57Bl/6 mice were subjected to 18.5 min of warm ischemia followed by reperfusion. 
24 h after injury, 0.3 mg/kg formoterol was administered. A. Mice were euthanized 30 min after 
formoterol administration, and renal cortical Akt and ERK1/2 phosphorylation were measured by 
immunoblot. B. Mice were euthanized 24 h after formoterol administration. Renal cortical 
expression of the injury markers KIM-1 and NGAL was assessed by immunoblot analysis. C. 
Serum was obtained 24 h after AKI and 24 h after formoterol administration. BUN and SCr were 
measured. D. Mice were euthanized 24 h after formoterol administration, and renal cortical 
mitochondrial protein expression was measured by immunoblot analysis. Mean + SEM. N=4-8 *- 
p<0.05 vs. Sham, #- p<0.05 vs IR+0.3%DMSO, One-Way ANOVA with Fisher’s LSD test.  
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Numerous drugs are known to induce MB, and we have identified several compounds 
that induce MB to accelerate the recovery of renal function following AKI. Among these 
compounds are the SIRT1 activator SRT1720,230 the MEK/ERK inhibitor trametinib,632 the 
phosphodiesterase inhibitor sildenafil, the 5HT1F receptor agonist LY344864, and the β2AR 
agonist formoterol. Both formoterol and LY344864 are known to activate Gβγ-Akt-eNOS-
cGMP-dependent signaling to induce MB in vitro;541 however, while formoterol increases cAMP 
through Gαs-dependent signaling, LY344864 activates the inhibitory Gαi and also inhibits 
ERK1/2 phosphorylation. All of these compounds activate signaling pathways that converge upon 
PGC-1α to induce MB. However, it is unlikely that these drugs only upregulate genes associated 
with MB. It is therefore important to determine other potentially beneficial or deleterious 
pathways activated by these compounds. For example, mice could be subjected to renal IR (or 
other organ injury) and treated with different inducers of MB. Tissue from these mice would then 
be subjected to transcriptomic analysis to identify transcriptional networks that are affected by 
these compounds. Using a panel that includes GPCR ligands as well as more targeted drugs, the 
data may be used to determine the roles of specific components of signaling pathways on gene 
expression. Due to the heterogeneous population of AKI patients, these data will help identify 
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